uses of an il-6 receptor antibody to treat il-6-related diseases

专利摘要:
The present invention relates to a pharmaceutical composition for treating IL-6 related diseases having an IL-6 inhibitor as an active ingredient, wherein the pharmaceutical composition is administered as usual after a short interval dosing period where the same dose as the usual dose is administered in a shorter interval than the usual dosage interval.
公开号:BR112017014067B1
申请号:R112017014067-5
申请日:2016-02-26
公开日:2021-01-12
发明作者:Takahiro Kakehi；Akinori Yamada；Yoshimasa Ishida
申请人:Chugai Seiyaku Kabushiki Kaisha；
IPC主号:

专利说明:

Technical Field
[001] The present invention relates to pharmaceutical compositions or dosage regimens used to treat diseases related to IL-6. Background of the Technique
[002] Interleukin-6 (IL-6) is a cytokine also referred to as B-cell stimulating factor 2 (BSF2) or β2 interferon. IL-6 was discovered as a differentiating factor involved in the activation of B lymphoid cells (Non-Patent Document 1), and was later discovered to be a multifunctional cytokine that affects the functions of a variety of cells (Non-Patent Document two). IL-6 has been reported to induce maturation of T lymphoid cells (Non-Patent Document 3).
[003] IL-6 transmits its biological activity through two types of proteins in cells. One is the IL-6 receptor, which is a ligand-binding protein that has a molecular weight of approximately 80 kD to which IL-6 binds (Non-Patent Documents 4 and 5). The IL-6 receptor exists as a soluble IL-6 receptor, which is mainly composed of its extracellular region, in addition to a membrane-bound form expressed on the cell membrane and penetrates through the cell membrane.
[004] The other is the gp130 membrane protein, which has a molecular weight of about 130 kDa and is involved in signal transduction other than ligand binding. The biological activity of IL-6 is transmitted in a cell through the formation of an IL-6 / IL-6 receptor complex by IL-6 and the IL-6 receptor, followed by binding of the complex with gp130 (Document that Not Patent 6).
[005] IL-6 inhibitors are substances that inhibit the transmission of biological activity of IL-6. So far, antibodies against IL-6 (anti-IL-6 antibodies), antibodies against IL-6 receptor (anti-IL-6 receptor antibodies), antibodies against gp130 (anti-gp130 antibodies), variants of IL- 6, partial IL-6 peptides or the IL-6 receptor, and likewise have been known.
[006] There are several reports with respect to anti-IL-6 receptor antibodies (Non-Patent Documents 7 and 8, and Patent Documents 1 to 3). One is a humanized PM-1 antibody obtained by transplanting the complementarity determining region (CDR) of mouse PM-1 antibody (Non-Patent Document 9) into a human antibody (Patent Document 1).
[007] Tocilizumab, which is an anti-IL-6 receptor antibody, is currently used to treat inflammatory diseases such as rheumatoid arthritis and Castleman's disease (Non-Patent Document 10), and it has also been confirmed to be effective for diseases such as neuromyelitis optica (NMO) (Non-Patent Document 11).
[008] The therapeutic effects of IL-6 antibodies on myasthenia gravis have also been reported (Non-Patent Document 12).
[009] Humanized antibodies such as tocilizumab are first generation antibody pharmaceuticals. Second generation antibody pharmaceuticals are currently being developed to improve drug efficacy, convenience, and cost of first generation antibody pharmaceuticals (Patent Document 2). As a second generation pharmaceutical antibody, SA237, a new IL-6 antireceptor antibody, has been produced by applying enhancement technologies such as those to enhance effector function, antigen-binding capacity, pharmacokinetics, and stability, or those for reduce immunogenic risks, and have already entered clinical trials.
[010] Although many antibody treatments are currently being carried out, the attenuation of therapeutic effects due to the development of anti-antibodies has been confirmed in alentuzumab. In order to prevent this attenuation, it has been reported to be effective for administering a non-cell-binding mutant that can be administered in high doses, rather than inducing immunological tolerance by administering a high dose of alentuzumab (Document that does not of Patent 13).
[011] The prior art documents related to the invention of this application are shown below. Prior Art Documents [Non-Patent Document] [Non-Patent Document 1] Hirano, T. et al., Nature (1986) 324, 73 - 76 [Non-Patent Document 2] Akira, S. et al ., Adv. In Immunology (1993) 54, 1 - 78 [Non-Patent Document 3] Lotz, M. et al., J. Exp. Med. (1988) 167, 1253 - 1258 [Non-Patent Document 4] Taga, T. et al., J. Exp. Med. (1987) 166, 967 - 981 [Non-Patent Document 5] Yamasaki, K. et al., Science (1988) 241, 825 - 828 [ Non-Patent Document 6] Taga, T. et al., Cell (1989) 58, 573 - 581 [Non-Patent Document 7] Novick, D. et al., Hybridoma (1991) 10, 137 - 146 [ Non-Patent Document 8] Huang, YW et al., Hybridoma (1993) 12, 621 - 630 [Non-Patent Document 9] Hirata, Y. et al., J. Immunol. (1989) 143, 2900 - 2906 [Non-Patent Document 10] Nishimoto, N. et al., Blood. Oct. 15, 2005; 106 (8): 2627 - 32 [Non-Patent Document 11] Araki et al., Mod. Rheumatol. (2013) 23 (4), 827 - 831 [Non-Patent Document 12] Aricha, R. et al., J. Autoimmun. (2011) 36 (2), 135 - 141 [Non-Patent Document 13] Charlotte L. et al., Nature Reviews Rheumatology (2010) 6, 558 - 559 [Patent Document] [Patent Document 1] Publication of International Patent Application No. WO 92-19759 [Patent Document 2] Publication of International Patent Application No. WO 2010/035769 Summary of the Invention [Problems to be solved by the invention]
[012] Even with SA237 (an antibody having the heavy chain sequence of SEQ ID NO: 3 and the light chain sequence of SEQ ID NO: 4), which is produced by applying technologies to reduce immunogenicity, in one study Phase I (SA-001JP) of subcutaneously administering a single 120 mg dose of SA237 to healthy adult male subjects, anti-SA237 antibodies were generated in 54.2% of cases (39 out of 72 cases) and an immunogenic problem occurred. An objective of the present invention is to suppress the generation of anti-antibody and to provide more effective pharmaceutical compositions or dosage regimens to be used in the treatment of IL-6 related diseases. [Means to Solve Problems]
[013] To solve the problems mentioned above, the present inventors focused on immunological tolerance, and found that the generation of anti-antibody can be suppressed by administering a pharmaceutical composition with a predetermined method and dose of administration.
[014] More specifically, the present inventors have found that the generation of anti-antibody can be suppressed using a pharmaceutical composition administered in a predetermined dose and method of administration to treat IL-6-related diseases, and have thus concluded the present invention.
[015] Specifically, the present invention includes the following: [1] A pharmaceutical composition for use in the treatment of an IL-6 related disease comprising an IL-6 inhibitor as an active ingredient, wherein the pharmaceutical composition is routinely administered after a short interval dosing period where the same dose as the routine dose is administered multiple times over a shorter interval than the routine dosing interval. [2] The pharmaceutical composition of [1], where the routine dosage interval is three to five weeks. [3] The pharmaceutical composition of [1], where the routine dosing interval is four weeks. [4] The pharmaceutical composition of any of [1] to [3], wherein the dosing interval during the short interval dosing period where the dose is administered multiple times over a shorter interval than the dosing interval routine is one to two weeks. [5] The pharmaceutical composition of any of [1] to [3], wherein the dosing interval during the short interval dosing period where the dose is administered multiple times over a shorter interval than the dosing interval routine is two weeks. [6] The pharmaceutical composition of any one from [1] to [5], where the short interval dosing period is four weeks from the initial administration. [7] The pharmaceutical composition of any one from [1] to [6], where the routine dose is 50 mg to 800 mg per administration. [8] The pharmaceutical composition of any of [1] to [7], where the routine dose is 120 mg per administration. [9] The pharmaceutical composition of any one of [1] to [8], wherein the IL-6 inhibitor is an anti-IL-6 receptor antibody. [10] The pharmaceutical composition of [9], wherein the anti-IL-6 receptor antibody is a chimeric antibody, a humanized antibody, or a human antibody. [11] The pharmaceutical composition of [9], wherein the anti-IL-6 receptor antibody comprises a heavy chain variable region having the sequence of SEQ ID NO: 1 and a light chain variable region having the sequence of SEQ ID NO: 2. [12] The pharmaceutical composition of [9], wherein the anti-IL-6 receptor antibody comprises a heavy chain having the sequence of SEQ ID NO: 3 and a light chain having the sequence of SEQ ID NO: 4. [13] The pharmaceutical composition of [9], wherein the anti-IL-6 receptor antibody is SA237. [14] The pharmaceutical composition of anyone from [1] to [13], in which the IL-6 related disease is rheumatoid arthritis, juvenile idiopathic arthritis, systemic onset juvenile idiopathic arthritis, Castleman's disease, systemic lupus erythematosus ( Lupus nephritis, Crohn's disease, lymphoma, ulcerative colitis, anemia, vasculitis, Kawasaki's disease, Still's disease, amyloidosis, multiple sclerosis, transplantation, age-related macular degeneration, ankylosing spondylitis, psoriasis, psoriatic arthritis, lung disease chronic obstructive (COPD), IgA nephropathy, osteoarthritis, asthma, diabetic nephropathy, GVHD, endometriosis, hepatitis (NASH), myocardial infarction, arteriosclerosis, sepsis, osteoporosis, diabetes, multiple myeloma, prostate cancer, kidney cancer, non-lymphoma -Hodgkin B cells, pancreatic cancer, lung cancer, esophageal cancer, colon cancer, cancer-associated cachexia, cancer nerve invasion, myocardial infarction, choroidal neovascularization associated with myopia, idiopathic choroidal neovascularization, uveitis, chronic thyroiditis, delayed hypersensitivity, contact dermatitis, atopic dermatitis, mesothelioma, polymyositis, dermatomyositis, panuveitis, anterior uveitis, intermediate uveitis, scleritis, keratitis, orbital inflammation, optic neuritis , dry eye syndrome, postoperative inflammation, neuromyelitis optica, myasthenia gravis, or pulmonary hypertension. [15] The pharmaceutical composition of any one of [1] to [14], wherein the pharmaceutical composition is a formulation for subcutaneous administration. [16] A method to treat an IL-6 related disease comprising administering an IL-6 inhibitor, in which the IL-6 inhibitor is routinely administered after a short interval dosing period where the same dose as the dose Routine is administered multiple times over a shorter interval than the routine dosing interval. [17] An IL-6 inhibitor for use in the treatment of an IL-6 related disease, in which the IL-6 inhibitor is routinely administered after a short interval dosing period where the same dose as the dose Routine is administered multiple times over a shorter interval than the routine dosing interval. [18] Use of an IL-6 inhibitor for the manufacture of a drug for the treatment of an IL-6 related disease, in which the IL-6 inhibitor is routinely administered after a short interval dosing period where the same dose as the routine dose is administered multiple times over a shorter interval than the routine dosing interval. Effects of the Invention
[016] The pharmaceutical composition or regimen of the present invention can solve the immunogenic problem of generating anti-drug antibody, and provide a pharmaceutical composition with less burden to the patient since it does not expose the patient to high doses. Brief Description of Drawings
[017] Fig. 1 indicates changes in the mean value (and standard deviation) of the serum SA237 concentration. Fig. 1a shows changes in the concentration of SA237 during the primary evaluation period, Fig. 1b shows changes in the concentration of SA237 during the extension period, and Fig. 1c shows changes in the concentration of serum SA237 up to week 8.
[018] Fig. 2 indicates changes in the mean value (and standard deviation) of the serum sIL-6R concentration, which is the pharmacodynamic marker of SA237. Fig. 2a shows changes in the concentration of sIL-6R during the primary evaluation period, and Fig. 2b shows changes in the concentration of serum sIL-6R during the extension period.
[019] Fig. 3 indicates the change in the mean value (and standard deviation) of the serum CRP concentration which is the pharmacodynamic generator of SA237. Fig. 3a shows changes in the CRP concentration during the primary evaluation period, and Fig. 3b shows changes in the CRP concentration during the extension period. Mode for Carrying Out the Invention
[020] Here below, the present invention will be described in detail.
[021] The present invention relates to pharmaceutical compositions or dosage regimens to be used in the treatment of diseases related to IL-6.
[022] "IL-6 inhibitors" of the present invention are substances that block signal transduction by IL-6, and inhibit the biological activities of IL-6. IL-6 inhibitors are preferably substances that have inhibitory effects against binding to anyone of IL-6, IL-6 receptor, and gp130.
[023] Examples of an IL-6 inhibitor of the present invention include, but are not particularly limited to, anti-IL-6 antibodies, anti-IL-6 receptor antibodies, anti-gp130 antibodies, IL-6 variants, variants of soluble IL-6 receptor, or partial peptides of IL-6 or IL-6 receptor, and low molecular weight substances showing similar activity. Examples of an IL-6 inhibitor of the present invention can preferably be IL-6 receptor recognition antibodies.
[024] The origin of the antibodies of the present invention is not particularly limited, but it is preferably a mammal and more preferably a human being.
[025] An anti-IL-6 antibody used in the present invention can be obtained as a polyclonal or monoclonal antibody using known methods. A mammal-derived monoclonal antibody is particularly preferred for the anti-IL-6 antibody used in the present invention. Mammalian-derived monoclonal antibodies include those produced by a hybridoma and those produced by a host transformed with an expression vector containing a gene. antibody using genetic engineering methods. Upon binding to IL-6, this antibody inhibits the binding of IL-6 to an IL-6 receptor, and blocks the transduction of the biological activity of IL-6 in cells.
[026] Examples of such an antibody include the MH166 antibody (Matsuda, T. et al., Eur. J. Immunol. (1988) 18, 951 - 956) and the SK2 antibody (Sato, K. et al., The abstracts of the 21st Annual Meeting of the Japanese Society for Immunology (1991) 21, 166).
[027] Basically, hybridomas that produce an anti-IL-6 antibody can be produced using techniques known as below. Specifically, hybridomas can be produced by immunizing by a conventional immunization method using IL-6 as a sensitizing antigen, fusing the resulting immune cells with precursor cells known by a conventional cell fusion method, and then screening for cells that produce monoclonal antibodies using a conventional screening method.
[028] Specifically, anti-IL-6 antibodies can be produced as below. Human IL-6 to be used as a sensitizing antigen to obtain antibodies can be obtained, for example, using the IL-6 and / or amino acid gene sequences disclosed in Eur. J. Biochem (1987) 168, 543 - 550; J. Immunol. (1988) 140, 1534-1541; and Agr. Biol. Chem. (1990) 54, 2685 - 2688.
[029] After an appropriate host cell is transformed with a known expression vector system inserted with an IL-6 gene sequence, the target IL-6 protein is purified from inside the host cell or from the culture supernatant using a known method. This purified IL-6 protein can be used as a sensitizing antigen. Alternatively, an IL-6 protein fusion protein and another protein can be used as a sensitizing antigen.
[030] An anti-IL-6 receptor antibody used in the present invention can be obtained as a polyclonal or monoclonal antibody using known methods. A monoclonal antibody derived from a mammal is particularly preferred over the anti-IL-6 receptor antibody used in the present invention. Monoclonal antibodies derived from a mammal include those produced by a hybridoma and those produced by a host transformed with an expression vector containing an antibody gene using genetic engineering methods. Upon binding to an IL-6 receptor, this antibody inhibits the binding of IL-6 to an IL-6 receptor, and blocks the transduction of biological IL-6 activity in cells.
[031] Examples of such an antibody include the MR16-1 antibody (Tamura, T. et al. Proc. Natl. Acad. Sci. USA (1993) 90, 11924 - 11928), PM-1 antibody (Hirata, Y. et al., J. Immunol. (1989) 143, 2900 - 2906), AUK12-20 antibody, AUK64-7 antibody, and AUK146-15 antibody (International Patent Application Publication No. WO 92-19759). Among them, the PM-1 antibody is listed as an example of a preferred monoclonal antibody against the human IL-6 receptor, and the MR16-1 antibody is listed as an example of a preferred monoclonal antibody against the IL-6 receptor of mouse.
[032] Basically, hybridomas that produce an anti-IL-6 receptor monoclonal antibody can be produced using techniques known as below. Specifically, hybridomas can be produced by immunizing by a conventional immunization method using an IL-6 receptor as a sensitizing antigen, fusing the resulting immune cells with precursor cells known by a conventional cell fusion method, and then screening for cells that produce monoclonal antibodies using a conventional screening method.
[033] Specifically, anti-IL-6 receptor antibodies can be produced as below. A human IL-6 receptor or mouse IL-6 receptor to be used as a sensitizing antigen to obtain antibodies can be obtained, for example, using the IL-6 receptor and / or amino acid gene sequences respectively disclosed in European Patent Application Publication No. EP 325474 and Japanese Patent Application Publication No (JP-A) H03-155795 (published, unexamined Japanese patent application).
[034] There are two types of IL-6 receptor proteins: one expressed on the cell membrane and the other separated from the cell membrane (soluble IL-6 receptor) (Yasukawa, K. et al., J. Biochem. (1990 ) 108, 673 - 676). The soluble IL-6 receptor is essentially composed of the extracellular region of the IL-6 receptor bound to the cell membrane, and differs from the membrane-bound IL-6 receptor in that it lacks the transmembrane region or both the transmembrane and intracellular. Any IL-6 receptor can be used as the IL-6 receptor protein, as long as it can be used as a sensitizing antigen to produce an anti-IL-6 receptor antibody to be used in the present invention.
[035] After an appropriate host cell is transformed with a known expression vector system inserted with an IL-6 receptor gene sequence, the target IL-6 receptor protein is purified from inside the host cell or from the culture supernatant using a known method. This purified IL-6 receptor protein can be used as a sensitizing antigen. Alternatively, a cell that expresses the IL-6 receptor or an IL-6 receptor protein fusion protein and another protein can be used as a sensitizing antigen.
[036] An anti-gp130 antibody used in the present invention can be obtained as a polyclonal or monoclonal antibody using known methods. A monoclonal antibody derived from a mammal is particularly preferred over the anti-gp130 antibody used in the present invention. Monoclonal antibodies derived from a mammal include those produced by a hybridoma and those produced by a host transformed with an expression vector containing an antibody gene using a genetic engineering method. Upon binding to gp130, this antibody inhibits the binding of an IL-6 / IL-6 receptor complex to gp130, and blocks the transduction of biological IL-6 activity in cells.
[037] Examples of such an antibody include the AM64 antibody (JP-A (Kokai) H03-219894), antibodies 4B11 and 2H4 (US 5571513), and the antibodies B-S12 and B-P8 (JP-A (Kokai) H08-291199).
[038] Basically, hybridomas that produce an anti-gp130 monoclonal antibody can be produced using techniques known as below. Specifically, hybridomas can be produced by immunizing by a conventional immunization method using gp130 as a sensitizing antigen, fusing the resulting immune cells with precursor cells known by a conventional cell fusion method, and then screening for cells that produce monoclonal antibodies using a conventional screening method.
[039] Specifically, monoclonal antibodies can be produced as below. For example, gp130 to be used as a sensitizing antigen to obtain antibodies can be obtained using the gp130 and / or amino acid gene sequences disclosed in European Patent Application Publication No. EP 411946.
[040] After an appropriate host cell is transformed with a known expression vector system inserted with a gp130 gene sequence, the target gp130 protein is purified from inside the host cell or from the culture supernatant using a known method. This purified gp130 protein can be used as a sensitizing antigen. Alternatively, a cell that expresses gp130 or a gp130 protein fusion protein and another protein can be used as a sensitizing antigen.
[041] Mammals to be immunized with a sensitizing antigen are not particularly limited, but are preferably selected in consideration of compatibility with precursor cells used for cell fusion. Typically, rodents such as mice, rats, and hamsters are used.
[042] Animals are immunized with a sensitizing antigen according to known methods. Typically, immunization is carried out, for example, by intraperitoneal or subcutaneous injection of a mammalian sensitizing antigen. Specifically, it is preferable to dilute or suspend the sensitizing antigen in phosphate buffered saline (PBS), physiological saline, and the like, to an appropriate volume, and mix it with an appropriate amount of a conventional adjuvant such as complete adjuvant of Freund if desired and emulsify, and then administer to the mammal every four to 21 days for several times. An appropriate carrier can also be used for immunization with the sensitizing antigen.
[043] After immunizing the mammal in this way, and confirming that the serum level of a desired antibody has increased, immunized cells are removed from the mammal and subjected to cell fusion. Spleen cells are particularly preferred as the immunized cells to undergo cell fusion.
[044] Mammalian myeloma cells are used as precursor cells to be fused with the immunized cells. So far, several known cell lines such as P3X63Ag8.653 (Kearney, JF et al., J. Immunol (1979) 123, 1548 - 1550), P3X63Ag8U.1 (Current Topics in Microbiology and Immunology (1978) 81, 1 - 7), NS-1 (Kohler, G. and Milstein, C., Eur. J. Immunol. (1976) 6, 511 - 519), MPC-11 (Margulies, DH et al., Cell (1976) 8 , 405 - 415), SP2 / 0 (Shulman, M. et al., Nature (1978) 276, 269 - 270), F0 (from St. Groth, SF et al., J. Immunol. Methods (1980) 35 , 1 - 21), S194 (Trowbridge, IS, J. Exp. Med. (1978) 148, 313 - 323), and R210 (Galfre, G. et al., Nature (1979) 277, 131 - 133) are properly used.
[045] Basically, cell fusion of the previously mentioned immune cells with myeloma cells can be performed according to known methods such as the method of Milstein et al. (Kohler, G. and Milstein, C., Methods Enzymol. (1981) 73, 3 - 46).
[046] More specifically, cell fusion is carried out, for example, in a conventional nutrient culture medium in the presence of a cell fusion promoter. For example, polyethylene glycol (PEG) or Sendai virus (HVJ) is used as the fusion promoter, and if desired, an adjuvant such as dimethyl sulfoxide can be added for use in improving fusion efficiency.
[047] The ratio of immune cells to myeloma cells used is preferably, for example, 1 to 10 immune cells for each myeloma cell. The culture medium used for cell fusion is, for example, an RPMI1640 or MEM culture medium suitable for the proliferation of myeloma cell lines. Other conventional culture media used for this type of cell culture can also be used. In addition, serum supplements such as fetal calf serum (FCS) can also be used in combination.
[048] For cell fusion, the fusion cells (hybridomas) of interest are formed by thoroughly mixing predetermined amounts of the previously mentioned immune cell and myeloma cell in the aforementioned culture medium, adding a PEG solution (for example , a PEG solution with an average molecular weight of about 1,000 to 6,000) preheated to about 37 ° C, usually in a concentration of 30% to 60% (w / v), and then mixing them. Then, cell fusion agents and such that are unsuitable for hybridoma growth can be removed by repeating the operation of sequentially adding an appropriate culture medium and removing the supernatant by centrifugation.
[049] Hybridomas are selected by growing in a general selection culture medium, for example, the HAT culture medium (a culture medium containing hypoxanthine, aminopterin, and thymidine). Culture in the HAT culture medium is continued for a sufficient period, usually from several days to several weeks, to kill the cells except for the hybridomas of interest (infused cells). Then, a standard limiting dilution method is performed to screen for and clone hybridomas that produce an antibody of interest.
[050] In addition to obtaining hybridomas by immunizing non-human animals with an antigen, desired human antibodies having a binding activity to a desired antigen or cell that expresses antigens can be obtained by sensitizing a human lymphocyte with an antigenic protein or cell which expresses desired antigen in vitro, and fusing the sensitized B lymphocyte with a human myeloma cell such as U266 (see, Japanese Patent Application No. Kokoku Publication (JP-B) H01-59878 (Japanese Patent Application approved, examined published for opposition)). In addition, an antigen or cell that expresses antigen can be administered to a transgenic animal having a repertoire of human antibody genes, and then a desired human antibody can be obtained using the aforementioned method (see, International Patent Application Publications Nos. WO 93/12227, WO 92/03918, WO 94/02602, WO 94/25585, WO 96/34096, and WO 96/33735).
[051] Hybridomas prepared as such that produce monoclonal antibodies can be subcultured in a conventional culture medium and stored in liquid nitrogen for a long period.
[052] To obtain monoclonal antibodies from hybridomas, the following methods can be used: grow the hybridomas according to conventional methods and obtain the antibodies as a culture supernatant or proliferate the hybridomas by administering them to a compatible mammal and obtaining the ascites antibodies; and so on. The former is suitable for obtaining antibodies with high purity, and the latter is suitable for large scale antibody production.
[053] For example, hybridomas that produce anti-IL-6 receptor antibodies can be prepared by the method disclosed in JP-A (Kokai) H03-139293. Such a preparation can be carried out by injecting hybridomas that produce PM-1 antibodies into the abdominal cavity of a BALB / c mouse, obtaining ascites, and then purifying the PM-1 antibodies from ascites; or by cultivating hybridomas in an appropriate medium (such as RPMI 1640 medium containing 10% fetal bovine serum, and 5% BM-Condimed H1 (Boehringer Mannheim); the hybridoma SFM medium (GIBCO-BRL); or the PFHM-II medium (GIBCO-BRL)) and then purifying the PM-1 antibodies from the culture supernatant.
[054] Recombinant antibodies can be used as the monoclonal antibodies of the present invention, wherein the recombinant antibodies are produced using genetic recombination techniques by cloning an antibody gene from a hybridoma, inserting the gene into an appropriate vector, and then introducing the vector into a host (see, for example, Borrebaeck, CAK and Larrick, JW, THERAPEUTICAL MONOCLONAL ANTIBODIES, Published in the United Kingdom by MACMILLAN PUBLISHERS LTD, 1990).
[055] More specifically, mRNAs that encode variable antibody (V) regions are isolated from cells that produce antibodies of interest, such as hybridomas. mRNAs can be isolated by preparing total RNAs according to known methods, such as the guanidine ultracentrifugation method (Chirgwin, JM et al., Biochemistry (1979) 18, 5294 - 5299) and the AGPC method (Chomczynski, P. et al., Anal. Biochem. (1987) 162, 156 - 159), and preparing mRNAs using an mRNA Purification Kit (Pharmacia) and the like. Alternatively, mRNAs can be directly prepared using the QuickPrep mRNA Purification Kit (Pharmacia).
[056] cDNAs from antibody V regions are synthesized from mRNAs obtained using reverse transcriptase. cDNAs can be synthesized using the AMV Reverse Transcriptase First Strand cDNA Synthesis Kit and the like. In addition, to synthesize and amplify cDNAs, the 5'-RACE method (Frohman, MA et al., Proc. Natl. Acad. Sci. USA (1988) 85, 8998 - 9002; Belyavsky, A. et al., Nucleic Acids Res. (1989) 17, 2919 - 2932) using the 5'-Ampli FINDER RACE Kit (Clontech) and PCR can be used. A DNA fragment of interest is purified from the obtained PCR products and then ligated with a vector DNA. Then, a recombinant vector is prepared using the above, and introduced into Escherichia coli and the like, and then its colonies are selected to prepare a desired recombinant vector. The nucleotide sequence of the DNA of interest is confirmed by a known method such as the dideoxy method.
[057] When a DNA encoding the V region of the antibody of interest is obtained, the DNA is ligated with a DNA encoding the constant region (region C) of a desired antibody, and inserted into an expression vector. Alternatively, a DNA encoding an antibody V region can be inserted into an expression vector comprising an antibody C region DNA.
[058] To produce an antibody to be used in the present invention, an antibody gene is inserted into an expression vector such that it is expressed under the control of an expression regulation region such as a enhancer and promoter, as described below . Then, the antibody can be expressed by transforming a host cell with this expression vector.
[059] In the present invention, artificially modified recombinant antibodies, for example, chimeric antibodies, humanized antibodies, or human antibodies can be used, for example, to reduce heteroantigenicity against humans. These modified antibodies can be prepared using known methods.
[060] A chimeric antibody can be obtained by ligating a DNA encoding an antibody V region obtained as above with a DNA encoding a human antibody C region, inserting it into an expression vector, and introducing the vector into a host for producing the chimeric antibody (see, European Patent Application Publication No. EP 125023; International Patent Application Publication No. WO 92-19759). This known method can be used to obtain chimeric antibodies useful for the present invention.
[061] Humanized antibodies are also referred to as reformed human antibodies or antibodies manufactured in the human type. They are produced by transplanting the complementarity-determining regions (CDRs) of an antibody from a non-human mammal (for example, a mouse) into the CDRs of a human antibody. General methods for this gene recombination are also known (see, European Patent Application Publication No. EP 125023, International Patent Application Publication No. WO 92-19759).
[062] More specifically, DNA sequences designed to link the CDRs of a mouse antibody with the framework regions (FRs) of a human antibody are synthesized by PCR from various oligonucleotides produced to contain overlapping portions at their ends. The obtained DNA is ligated with a DNA encoding a human antibody C region and inserted into an expression vector, and the expression vector is introduced into a host to produce the humanized antibody (see, European Patent Application Publication No EP 239400, International Patent Application Publication No. WO 92 - 19759).
[063] Human antibody FRs to be linked via CDRs are selected so that the CDRs form satisfactory antigen binding sites. The amino acid (s) within the framework regions of the variable antibody regions can be replaced as needed so that the CDRs of the reformed human antibody form appropriate antigen-binding sites (Sato, K. et al., Cancer Res (1993) 53, 851 - 856).
[064] Human antibody C regions are used for chimeric and humanized antibodies. Examples of human antibody C regions include CY, and for example, CY1, CY2, CY3, or CY4 can be used. In addition, to improve the stability of antibodies or their production, human antibody C regions can be modified.
[065] Chimeric antibodies are composed of the variable region of an antibody derived from a non-human mammal and the C region derived from a human antibody; and humanized antibodies are composed of the CDRs of an antibody derived from a non-human mammal and the framework regions and C regions derived from a human antibody. Their antigenicity in the human body is reduced, and thus they are useful as antibodies for use in the present invention.
[066] Preferred specific examples of humanized antibodies for use in the present invention include a humanized PM-1 antibody (see, International Patent Application Publication No. WO 92-19759).
[067] In addition, in addition to the previously mentioned methods for obtaining human antibodies, techniques for obtaining human antibodies by panning using a human antibody library are also known. For example, the variable region of a human antibody can be expressed on a phage surface as a single chain antibody (scFv) using the phage display method, and antigen-binding phages can then be selected. By analyzing the genes of the selected phages, the DNA sequence encoding the variable region of the human antibody that binds to the antigen can be determined. Once the DNA sequence of a scFv that binds to the antigen is revealed, an appropriate expression vector comprising the sequences can be prepared to obtain a human antibody. These methods are already known, and the publications, WO 92/01047, WO 92/20791, WO93 / 06213, WO 93/11236, WO 93/19172, WO 95/01438, and WO 95/15388, can be used as references .
[068] The antibody gene constructed as described above can be expressed according to known methods. When a mammalian cell is used, the antibody gene can be expressed using a DNA in which an effective promoter gene is commonly used, the antibody gene to be expressed, and a poly A signal on the 3 'side (downstream) of the antibody gene are operably linked together, or using a vector comprising the DNA. Examples of a promoter / enhancer include the immediate human cytomegalovirus initial promoter / enhancer.
[069] In addition, other promoters / enhancers that can be used to express antibodies for use in the present invention include retrovirus viral promoters / enhancers, polyoma viruses, adenoviruses, simian viruses 40 (SV40), and the like; and promoters / enhancers derived from mammalian cells such as human elongation factor 1α (HEF1α).
[070] The expression can be easily performed, for example, following the method in Mulligan et al. (Mulligan, R. C. et al., Nature (1979) 277, 108 - 114) when using the SV40 promoter / enhancer, or following the method in Mizushima et al. (Mizushima, S. and Nagata S., Nucleic Acids Res. (1990) 18, 5322) when using the HEF1α promoter / enhancer.
[071] When E. coli is used, the antibody gene can be expressed by operatively linking a commonly used effective promoter gene, a signal sequence for antibody secretion, and the antibody gene to be expressed. Examples of the promoter include a lacZ promoter and an araB promoter. A lacZ promoter can be used according to the method of Ward et al. (Ward, E. S. et al., Nature (1989) 341, 544 - 546; Ward, E. S. et al., FASEB J. (1992) 6, 2422 - 2427); and an araB promoter can be used according to the method of Better et al. (Better, M. et al., Science (1988) 240, 1041-1043).
[072] When the antibody is produced in the E. coli periplasm, the signal sequence of pel B (Lei, SP et al., J. Bacteriol. (1987) 169, 4379 - 4383) can be used as a sequence of signal for antibody secretion. The antibody produced in the periplasm is isolated, and then appropriately refolded in the antibody structure to be used (see, for example, WO 96/30394).
[073] As the origin of replication, those derived from SV40, polyoma virus, adenovirus, bovine papilloma virus (BPV) and the like can be used. In addition, to increase the gene copy number in a host cell system, the expression vector can comprise the aminoglycoside phosphotransferase (APH) gene, thymidine kinase (TK) gene, xanthine-guanine phosphoribosyltransferase (Ecogpt) gene E. coli, dihydrofolate reductase (dhfr) gene, and the like, as a selection marker.
[074] Any production system can be used to prepare antibodies for use in the present invention. Production systems for antibody preparation include in vitro and in vivo production systems. In vitro production systems include those using eukaryotic cells or those using prokaryotic cells.
[075] When eukaryotic cells are used, production systems include those using animal cells, plant cells, or fungal cells. Such animal cells include (1) mammalian cells such as CHO, COS, myeloma, neonate hamster kidney (BHK), HeLa, and Vero; (2) amphibian cells such as Xenopus oocytes; and (3) insect cells such as sf9, sf21, and Tn5. Known plant cells include cells derived from Nicotiana tabacum, which can be grown in callus. Known fungal cells include yeasts such as Saccharomyces (for example, Saccaromyces cerevisiae) and molds such as Aspergillus (for example, Aspergillus niger).
[076] When prokaryotic cells are used, production systems include those using bacterial cells. Known bacterial cells include E. coli and Bacillus subtilis.
[077] Antibodies can be obtained by introducing the antibody gene of interest into these cells by transformation, and then culturing the transformed cells in vitro. The cells are cultured according to known methods. For example, DMEM, MEM, RPMI 1640, or IMDM can be used as the culture medium, and serum supplements such as fetal calf serum (FCS) can be used in combination. Alternatively, cells introduced with the antibody gene can be transferred into the abdominal cavity and the like of an animal to produce antibodies in vivo.
[078] However, in vivo production systems include those using animals or those using plants. When using animals, production systems include those using mammals or insects.
[079] Mammals that can be used include goats, pigs, sheep, mice, and cattle (Vicki Glaser, SPECTRUM Biotechnology Applications, 1993). In addition, insects that can be used include silkworms. When using plants, tobacco and the like can be used.
[080] An antibody gene is introduced into these animals or plants, and antibodies are produced in the body of the animals or plants and then recovered. For example, an antibody gene can be prepared as a fusion gene by inserting it into the center of a gene that encodes a protein produced exclusively in milk, such as β goat casein. DNA fragments comprising the inserted fusion gene, which includes the antibody gene, are injected into goat embryos, and the embryos are introduced into female goats. The desired antibodies are obtained from the milk produced by transgenic goats born from the goats that received the embryos, or their progenies. When appropriate, transgenic goats can be supplied with hormones to increase the volume of milk containing the desired antibodies they produce (Ebert, K. M. et al., Bio / Thecnology (1994) 12, 699 - 702).
[081] When silkworms are used, silkworms are infected with a baculovirus inserted with the antibody gene of interest, and the desired antibodies are obtained from the body fluids of these silkworms (Maeda, S. et al., Nature (1985) 315, 592 - 594). In addition, when tobacco is used, the antibody gene of interest is inserted into a plant expression vector such as pMON530, and the vector is introduced into bacteria such as Agrobacterium tumefaciens. This bacterium is used to infect tobacco such as Nicotiana tabacum, and then the desired antibody is obtained from the leaves of this tobacco (Julian, K.-C. Ma et al., Eur. J. Immunol. (1994) 24, 131 - 138 ).
[082] When producing antibodies using in vitro or in vivo production systems as described above, DNAs encoding an antibody heavy chain (H chain) and light chain (L chain) can be inserted into separate expression vectors, and a host is then co-transformed with the vectors. Alternatively, DNA encoding the H chain and DNA encoding the L chain can be inserted into a single expression vector to transform a host (see International Patent Application Publication WO 94-11523).
[083] The antibodies used in the present invention can be antibody fragments or modified products thereof, as long as they can be used appropriately in the present invention. For example, antibody fragments include Fab, F (ab ') 2, Fv, and single chain Fv (scFv) in which the Fvs of the H and L chains are linked via an appropriate linker.
[084] Specifically, antibody fragments are produced by treating antibodies with enzymes such as papain or pepsin, or alternatively, by building genes that encode these antibody fragments and introducing them into expression vectors, and then expressing the vectors into appropriate host cells (see, for example, Co, MS et al., J. Immunol. (1994) 152, 2968 - 2976; Better, M. & Horwitz, AH, Methods in Enzymology (1989) 178, 476 - 496 ; Plueckthun, A. & Skerra, A., Methods in Enzymology (1989) 178, 497 - 515; Lamoyi, E., Methods in Enzymology (1989) 121, 652 - 663; Rousseaux, J. et al., Methods in Enzymology (1989) 121, 663 - 666; and Bird, RE et al., TIBTECH (1991) 9, 132 - 137).
[085] An scFv can be obtained by linking the H chain V region and the L chain V region of an antibody. In this scFv, the H-chain V region and the L-chain V region are linked via a linker, preferably via a peptide linker (Huston, JS et al., Proc. Natl. Acad. Sci. USA ( 1988) 85, 5879 - 5883). The V regions of the H and L chains in a scFv can be derived from any of the antibodies described above. Peptide linkers to link the V regions include, for example, an arbitrary single chain peptide consisting of 12 to 19 amino acid residues.
[086] A DNA encoding an scFv can be obtained by amplifying a portion of DNA encoding the desired amino acid sequence in standard PCR sequences using a primer pair that defines the ends of the portion, where a DNA encoding a H chain V region or H chain V and DNA encoding a L chain or L chain region of the previously mentioned antibodies are used as the standards, and then the amplified portion of DNA is further amplified with a DNA which encodes a peptide linker portion and a primer pair that defines both ends of the linker so that it can be attached to each of the H and L chains.
[087] Once a DNA encoding scFv has been prepared, an expression vector comprising the DNA and a host transformed with the expression vector can be obtained according to conventional methods. In addition, an scFv can be obtained according to conventional methods using the host.
[088] Similar to the above, antibody fragments can be produced by obtaining their genes, expressing them, and then using a host. An "antibody" as used herein encompasses similar antibody fragments.
[089] Antibodies linked to various molecules such as polyethylene glycol (PEG) can also be used as modified antibodies. An "antibody" as used herein encompasses similar modified antibodies. These modified antibodies can be obtained by chemically modifying the obtained antibodies. Such methods are already established in the art.
[090] Antibodies produced and expressed as above can be isolated from the inside or outside of cells or from hosts, and then purified until homogeneous. Antibodies for use in the present invention can be isolated and purified by affinity chromatography. Columns used for affinity chromatography include protein A columns and protein G columns. Carriers used for protein A columns include HyperD, POROS, and Sepharose F.F. Other methods used for the isolation and / or purification of common proteins can be used without limitation.
[091] For example, the antibodies used for the present invention can be isolated and purified by appropriately selecting and combining chromatographs except the affinity chromatography described above, filtration, ultrafiltration, reloading, dialysis, and the like. Examples of chromatographies include ion exchange chromatography, hydrophobic chromatography, and gel filtration. These chromatographies can be applied to high performance liquid chromatography (HPLC). Alternatively, reverse phase HPLC can be used.
[092] The concentration of the antibodies obtained as above can be determined by measuring absorbance, ELISA, and the like. Specifically, when using absorbance measurement, the concentration can be determined by appropriately diluting the antibody solution with PBS (-), measuring its absorbance at 280 nm, and calculating the concentration using the conversion 1.35 OD / 1 mg / ml. Alternatively, when using ELISA, the concentration can be determined as below. Specifically, 100 μl of goat anti-human IgG (TAG) diluted to 1 μg / ml with 0.1 M bicarbonate buffer (pH 9.6) is added to a 96 well plate (Nunc) and incubated during overnight at 4 ° C to immobilize the antibody. After blocking, 100 μl of an appropriately diluted antibody to be used in the present invention or an appropriately diluted sample comprising the antibody, or human IgG (CAPPEL) as a standard are added, and the plate is incubated for one hour at room temperature.
[093] After washing, 100 μl of anti-human IgG labeled with 5000 x diluted alkaline phosphatase (BIO SOURCE) is added, and the plate is incubated for one hour at room temperature. After another wash, the substrate solution is added, the plate is incubated, and the absorbance at 405 nm is measured using Model 3550 Microplate Reader (Bio-Rad) to calculate the concentration of the antibody of interest.
[094] The IL-6 variants used in the present invention are substances that have binding activity to an IL-6 receptor and do not transmit biological activity of IL-6. That is, variants of IL-6 compete with IL-6 for binding to an IL-6 receptor, but do not transmit biological activity of IL-6, and thus block IL-6-mediated signal transduction.
[095] IL-6 variants are produced by introducing mutation (s) by replacing amino acid residue (s) in the IL-6 amino acid sequence. Any IL-6 from which the IL-6 variant is derived can be used, but human IL-6 is preferred, considering antigenicity and the like.
[096] More specifically, amino acid substitutions are performed by predicting the secondary structure of IL-6 from the IL-6 amino acid sequence using known molecular modeling programs such as WHATIF (Vriend et al., J. Mol Graphics (1990) 8, 52 - 56), and evaluating the influence of the substituted amino acid residue (s) on the integral molecule. After determining the appropriate amino acid residue (s) to be replaced, mutation (s) are introduced by a PCR method commonly performed using a vector comprising a nucleotide sequence encoding an IL-6 gene human as a standard for causing amino acid substitution (s), and the gene encoding the IL-6 variant is thereby obtained. If necessary, this gene is inserted into an appropriate expression vector, and the IL-6 variant can be obtained according to the previously mentioned methods for expression, production, and purification of recombinant antibodies.
[097] Specific examples of IL-6 variants are disclosed in Brakenhoff et al., J. Biol. Chem. (1994) 269, 86 - 93; Savino et al., EMBO J. (1994) 13, 1357 - 1367; WO 96-18648; and WO 96-17869.
[098] Partial IL-6 peptides or the IL-6 receptor to be used in the present invention are substances that have binding activity to the IL-6 or IL-6 receptor, respectively, and that do not transmit biological activities of IL-6. That is, partial IL-6 or IL-6 receptor peptides bind to and capture the IL-6 or IL-6 receptor, and thereby specifically inhibit IL-6 binding to the IL-6 receptor. As a result, the biological activities of IL-6 are not transmitted, and thus, IL-6-mediated signal transduction is blocked.
[099] Partial IL-6 or IL-6 receptor peptides are peptides that are composed of the integral amino acid sequence of the region of the IL-6 amino acid sequence or IL-6 receptor or a part of it involved in linking IL-6 and the IL-6 receptor. Such peptides are usually composed of 10 to 80, preferably 20 to 50, more preferably 20 to 40 amino acid residues.
[0100] Partial IL-6 or IL-6 receptor peptides can be produced by specifying the region of the IL-6 amino acid sequence or IL-6 receptor involved in binding between IL-6 and the IL receptor -6, and applying generally known methods such as genetic engineering techniques and peptide synthesis methods to the integral amino acid sequence of the specific region or a portion thereof.
[0101] To prepare a partial IL-6 peptide or an IL-6 receptor by genetic engineering methods, a DNA sequence encoding the desired peptide is inserted into an expression vector, and then the peptide can be obtained by applying the previously mentioned methods for expressing, producing, and purifying recombinant antibodies are used.
[0102] To produce a partial IL-6 peptide or an IL-6 receptor by peptide synthesis methods, peptide synthesis methods commonly used such as solid phase synthesis methods and liquid phase synthesis methods can be used.
[0103] Specifically, peptides can be synthesized according to the method described in "The sequel of Development of Pharmaceuticals (Zoku Iyakuhin no Kaihatsu), Vol. 14, Peptide Synthesis (ed. Haruaki Yajima, 1991, Hirokawa Shoten)". As a solid phase synthesis method, the following method and the like can be used: binding of the amino acid corresponding to the C-terminus of the peptide to be synthesized to a support that is insoluble in organic solvents, and then prolonging the peptide filament by repeating alternately (1) the reaction of condensing amino acids whose α-amino groups and branched-chain functional groups are protected with appropriate protecting groups, one by one in a direction from termination C to termination N; and (2) the reaction to remove the protecting groups from the α-amino groups from the amino acids or peptides attached to the resin. Solid phase peptide synthesis is widely classified in the Boc method and the Fmoc method, depending on the type of protecting groups used.
[0104] After synthesizing the peptide of interest as above, the deprotection reaction and the peptide filament cleavage reaction of the support are carried out. For the peptide filament cleavage reaction, hydrogen fluoride or trifluoromethane sulfonic acid is generally used for the Boc method, and TFA is generally used for the Fmoc method. In the Boc method, for example, the protected peptide-bound resin is treated with hydrogen fluoride in the presence of anisole. Then, the peptide is recovered by removing the protecting groups and cleaving the peptide from its support. By lyophilizing the recovered peptide, a crude peptide can be obtained. In the Fmoc method, the deprotection reaction and the peptide filament cleavage reaction of the support can be performed in TFA and similar by operations similar to those described above.
[0105] The obtained crude peptides can be separated and purified using HPLC. Elution can be carried out under ideal conditions using a water-acetonitrile solvent system, which is generally used for protein purification. The fractions corresponding to the peaks of the obtained chromatographic profile are collected and freeze dried. Peptide fractions purified in this way are identified by molecular weight analysis by means of mass spectrum analysis, amino acid composition analysis, amino acid sequence analysis, and the like.
[0106] Specific examples of the partial IL-6 and IL-6 receptor peptides are disclosed in JP-A (Kokai) H02-188600, JP-A (Kokai) H07-324097, JP-A (Kokai) H08- 311098, and U.S. Patent Publication No. US5210075.
[0107] The antibodies used in the present invention can be conjugated antibodies that are linked to various molecules such as polyethylene glycol (PEG), radioactive substances, and toxins. Such conjugated antibodies can be obtained by chemically modifying the antibodies obtained. Methods for antibody modification have already been established in this field. Accordingly, the term "antibody" as used herein encompasses similar conjugated antibodies.
[0108] In the present invention, "IL-6 related disease" refers to an IL-6 related disease, and examples include rheumatoid arthritis, juvenile idiopathic arthritis, systemic onset juvenile idiopathic arthritis, Castleman's disease, lupus erythematosus systemic (SLE), lupus nephritis, Crohn's disease, lymphoma, ulcerative colitis, anemia, vasculitis, Kawasaki's disease, Still's disease, amyloidosis, multiple sclerosis, transplantation, age-related macular degeneration, ankylosing spondylitis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), IgA nephropathy, osteoarthritis, asthma, diabetic nephropathy, GVHD, endometriosis, hepatitis (NASH), myocardial infarction, arteriosclerosis, sepsis, osteoporosis, diabetes, multiple myeloma, prostate cancer, kidney cancer, non-Hodgkin's B-cell lymphoma, pancreatic cancer, lung cancer, esophageal cancer, colon cancer, cancer-associated cachexia, cancer nerve invasion, myocardial infarction, neovascularization the choroidal associated with myopia, idiopathic choroidal neovascularization, uveitis, chronic thyroiditis, delayed hypersensitivity, contact dermatitis, atopic dermatitis, mesothelioma, polymyositis, dermatomyositis, panuveitis, anterior uveitis, intermediate uveitis, scleritis, keratitis, neuritic inflammation, orbititis diabetic, proliferative vitreoretinopathy, dry eye syndrome, postoperative inflammation, neuromyelitis optica, myasthenia gravis, and pulmonary hypertension.
[0109] In the present invention, "routine dosage range" refers to a dosage range generally used for the pharmaceutical products mentioned above (pharmaceutical compositions of the present invention), for example, a dosage range for routine administration that can be described in a package insert as "subsequent doses should be administered at four-week intervals" and the like. The routine dosing interval in the present invention is not particularly limited, but examples include one day to 24 weeks, preferably two weeks to eight weeks, more preferably three to five weeks, and even more preferably four weeks. Routine dosing intervals can have a certain range.
[0110] In the present invention, "routine dose" is a dose commonly used for the pharmaceutical products mentioned above (pharmaceutical compositions of the present invention), for example, a generally administered dose that can be described in a package insert as "generally , a single dose is 8 mg per kg of body weight ". The routine dose in the present invention is not particularly limited, but the dose per administration can be, for example, two to 20 mg of IL-6 inhibitor per kg of body weight (2 to 20 mg / kg) or 50 mg at 800 mg IL-6 inhibitor, preferably two to eight mg IL-6 inhibitor per kg body weight (2 to 8 mg / kg) or 80 to 160 mg IL-6 inhibitor, or more preferably 8 mg of IL-6 inhibitor per kg of body weight (8 mg / kg) or 120 mg of IL-6 inhibitor.
[0111] In the present invention, "short interval dosing period" refers to a period of administration to induce immunological tolerance against drugs (pharmaceutical compositions of the present invention) to suppress the generation of anti-drug antibodies due to immunogenicity. The short interval dosing period in the present invention refers to a period where the same dose as the routine dose is administered multiple times over a shorter interval than the routine dosing interval. Although the short interval period is not particularly limited as long as it is a period where immunological tolerance is induced, the period is preferably one to eight weeks from the initial administration, and more preferably four weeks from the initial administration. "The same dose as the routine dose" includes doses that provide the same blood concentration of IL-6 inhibitor as a routine dose. "Interval shorter than the routine dosing interval" is not particularly limited as long as it is shorter than a routine dosing interval, and is preferably half a routine dosing interval, for example, two weeks when the routine dosing interval is four weeks. For example, the short interval dosing period may have a similar range as one to two weeks. "(Being) administered multiple times" refers to two or more administrations including the initial administration, and is preferably two to five administrations including the initial administration, more preferably three administrations including the initial administration. Whether immunological tolerance has been induced can be determined by looking at whether the generation of anti-drug antibodies is suppressed.
[0112] "Routine administration" in the present invention refers to a administration commonly used for the pharmaceutical products mentioned above (pharmaceutical compositions of the present invention), for example, administration in the "routine dose" and "dosage range of routine "described above.
[0113] Preferred examples of an "anti-IL-6 receptor antibody" of the present invention include tocilizumab which is an anti-humanized IL-6 receptor IgG1 antibody, and humanized anti-IL-6 receptor antibodies produced by modifying the variable and constant regions of tocilizumab, specifically, an antibody containing a variable region of heavy chain comprising the sequence of SEQ ID NO: 1 and a variable region of light chain comprising the sequence of SEQ ID NO: 2. A more preferable example is an antibody containing a heavy chain comprising the sequence of SEQ ID NO: 3 (heavy chain of SA237) and a light chain comprising the sequence of SEQ ID NO: 4 (light chain of SA237). SA237 is particularly preferred.
[0114] Such antibodies can be obtained according to the methods described in WO2010 / 035769, WO2010 / 107108, WO2010 / 106812, and the like. Specifically, antibodies can be produced using genetic recombination techniques known to those skilled in the art, based on the sequence of the anti-IL-6 receptor antibody mentioned above (see, for example, Borrebaeck CAK and Larrick JW, THERAPEUTIC MONOCLONAL ANTIBODIES, Published in United Kingdom by MACMILLAN PUBLISHERS LTD, 1990). A recombinant antibody can be obtained by cloning a DNA encoding the antibody from a hybridoma or antibody-producing cell such as an antibody-producing sensitized lymphocyte, inserting the DNA into an appropriate vector, and introducing the vector into a host (host cell) to produce the antibody.
[0115] Such antibodies can be isolated and purified using isolation and purification methods conventionally used for antibody purification, without limitation. For example, antibodies can be isolated and purified by selecting and appropriately combining column chromatography, filtration, ultrafiltration, reloading, solvent precipitation, solvent extraction, distillation, immunoprecipitation, SDS-gel polyacrylamide electrophoresis, isoelectric focusing , dialysis, recrystallization, and the like.
[0116] In the present invention, the routine administration period begins from the final administration of the short interval dosing period. More specifically, the final administration in the short interval dosing period is followed by a routine dosing interval, and then the first administration in the routine administration period is performed.
[0117] The pharmaceutical composition of the present invention is preferably a pharmaceutical composition in which the same dose of an IL-6 inhibitor as the routine dose is administered two to five times at intervals of one to three weeks from the initial administration in the short interval dosing period, and then the IL-6 inhibitor is administered at intervals of two to eight weeks starting from the final administration in the short interval dosing period using a routine dose of 50 mg to 800 mg per administration; or more preferably a pharmaceutical composition in which SA237 is administered three times in the same dose as the routine dose at two week intervals from the initial administration in the short interval dosing period (i.e., week 0, week 2, and week 4), and then SA237 is routinely administered at eight week intervals starting from the final administration in the short interval dosing period (ie week 12, week 20, week 28 and so on at eight week intervals, counting from the initial administration in the short interval dosing period) using a routine dose of 120 mg per administration.
[0118] The preferred administration schedule for the IL-6 inhibitor can be adjusted, for example, by appropriately extending the administration interval by monitoring disease conditions and changes in blood test values.
[0119] Pharmaceutical compositions of the present invention used for therapeutic or preventive purposes can be formulated to produce freeze-dried formulations or solution formulations by mixing, if necessary, with suitable pharmaceutically acceptable carriers, vehicles, and the like. Suitable pharmaceutically acceptable carriers and vehicles include, for example, sterile water, physiological saline, stabilizers, excipients, antioxidants (such as ascorbic acid), buffers (such as phosphate, citrate, histidine, and other organic acids), antiseptics , surfactants (such as PEG and Tween), chelating agents (such as EDTA), and binders. Other low molecular weight polypeptides, proteins such as serum albumin, gelatin, and immunoglobulins, amino acids such as glycine, glutamine, asparagine, glutamic acid, aspartic acid, methionine, arginine, and lysine, sugars and carbohydrates such as polysaccharides and monosaccharides, and sugar alcohols such as mannitol and sorbitol can also be contained. When preparing an aqueous solution for injection, physiological saline and isotonic solutions comprising glucose and other adjuvants such as D-sorbitol, D-mannose, D-mannitol, and sodium chloride can be used; and appropriate solubilizers such as alcohol (for example, ethanol), polyalcohols (such as propylene glycol and PEG), and non-ionic surfactants (such as polysorbate 80, polysorbate 20, poloxamer 188, and HCO-50) can be used in combination. By mixing hyaluronidase in the formulation, a larger volume of fluid can be administered subcutaneously (Expert Opin. Drug Deliv. Jul 2007; 4 (4): 427 - 40). In addition, syringes can be pre-filled with the pharmaceutical composition of the present invention. Solution formulations can be prepared according to the method described in WO2011 / 090088.
[0120] If necessary, the pharmaceutical compositions of the present invention can be encapsulated in microcapsules (for example, those manufactured from hydroxymethylcellulose, gelatin, and poly (methylmethacrylate)), or incorporated into colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsion, nanoparticles, and nanocapsules) (see, for example, "Remington's Pharmaceutical Science 16th edition", Oslo Ed. (1980)). Methods for preparing pharmaceutical agents as controlled-release pharmaceutical agents are also known, and similar methods can be applied to the pharmaceutical compositions of the present invention (Langer et al., J. Biomed. Mater. Res. 15: 267 - 277 (1981) ; Langer, Chemtech. 12: 98-105 (1982); U.S. Patent No. 3,773,919; European Patent Application Publication No. EP 58,481; Sidman et al., Biopolymers 22: 547 - 556 (1983); and EP 133,988 ).
[0121] The pharmaceutical composition of the present invention can be administered to a patient via any appropriate route. For example, it can be administered to a patient intravenously by bolus injection or by continuous infusion, intramuscularly, intraperitoneally, intracerebrospinally, transdermally, subcutaneously, intraarticularly, sublingually, intrasynovially, orally, by inhalation, locally, or externally, for a certain period. of time. Intravenous or subcutaneous administration is preferred.
[0122] All references to the prior art cited here are incorporated by reference in this specification. Examples
[0123] Here below, the present invention will be specifically described with reference to the Examples, but it should not be construed as being limited thereto. [Example 1] Preparation of IL-6 inhibitors
[0124] SA237, the anti-IL-6 receptor antibody described in the patent document, WO2010 / 035769 (an antibody containing a heavy chain having the sequence of SEQ ID NO: 26 of WO 2010/035769 (SEQ ID NO: 3 of this specification) and a light chain having the sequence of SEQ ID NO: 29 of WO 2010/035769 (SEQ ID NO: 4 of this specification) in WO2010 / 035769), was produced according to the description in the document of previously mentioned patent. The antibody produced was used to prepare formulations for subcutaneous administration by the method in WO2011 / 090088 patent document. [Example 2] Examination by single subcutaneous administration to healthy adult Japanese and Caucasian male subjects (SA001JP)
[0125] Safety, tolerability, pharmacokinetics, and bioavailability of SA237 when administered subcutaneously to healthy adult Japanese and Caucasian male subjects were assessed. In this study, SA237 was administered subcutaneously or intravenously by drip infusion to 48 Japanese subjects, and administered subcutaneously to 24 Caucasian subjects. Safety and tolerability in a single administration of SA237 were predominantly satisfactory in 24 cases. The absolute bioavailability of SA237 for subcutaneous administrations of 60 mg and 120 mg was 64.6% and 69.4%, respectively. The development of anti-SA237 antibodies was observed in 39 of 72 subjects administered with SA237. [Example 3] Comparative study of a parallel group, opened by multiple subcutaneous administration to Japanese patients with rheumatoid arthritis (SA-105JP)
[0126] Patients who meet the following criteria were selected as the subjects: (1) Diagnosed with rheumatoid arthritis (RA) according to the 1987 American College of Rheumatology (ACR) criteria; (2) Duration of RA disease for six months or more; (3) It showed a level of C-reactive protein (CRP) above the upper limit of the laboratory reference range in a test performed within two weeks before starting the administration of the investigational medicinal product (IMP); (4) The age of 20 years or older at the time of informed consent; (5) Signed the person's informed consent form; (6) Did not receive treatment with methotrexate (MTX) later or in 16 weeks before starting IMP administration; (7) Did not receive treatment with leflunomide later or in 12 weeks before starting IMP administration (or later or in four weeks before starting investigational agent administration, if treatment with standard cholestyramine or drug elimination was performed activated carbon); (8) Did not receive treatment with DMARD or immunosuppressive agents except those described above later or in four weeks before starting the administration of the investigative agent; and (9) Did not receive treatment exceeding 10 mg per day as prednisolone equivalence, later or in two weeks before starting the investigational agent administration.
[0127] The subjects were randomized into three groups (groups A, B, and C) according to the central registration method, and the parallel, open comparative group study was carried out (see Table 1). Randomization was stratified by body weight. This clinical study comprises a primary evaluation period, an extension period, and a follow-up period.
[0128] In the primary evaluation period, 120 mg of SA237 was administered at week 0, week 2, and week 4; and 120 mg, 60 mg, and 30 mg of SA237 were administered to groups A, B, and C, respectively, from week 8 to week 16 at four-week intervals. Subsequently, in principle, groups A, B, and C were observed until weeks 32, 28, and 24, respectively, during which time serum concentrations of SA237 were expected to be undetectable in each group (observation included anti-SA237 antibody measurements).
[0129] In the extension period, 120 mg of SA237 were administered at week 0, week 2, and week 4; and 120 mg of SA237 were administered from week 8 to 20 weeks at four-week intervals, and observation continued until week 32.
[0130] The test drug was in the form of a vial filled with 1.0 mL of a solution containing 120 mg of SA237. The solution contained L-histidine, L-arginine, L-aspartic acid, and polyoxyethylene (160) polyoxypropylene (30) glycol as additives, and was adjusted to pH 5.5 to 6.5. In principle, the drug was administered subcutaneously to the abdominal area. [Table 1] NUMBER OF CASES:

[0131] In pharmacokinetic and pharmacodynamic evaluations, and in the examination of efficacy (in the complete analysis setting (FAS)) and safety of repeatedly administering SA237 to patients with RA, the subjects' basics in the groups of 11 respective cases (33 cases in total ) submitted to each analysis was 59.0 to 65.0 years of age (median range for each of the groups; the same applies from now on) and 50.30 to 57.90 kg of body weight. The percentage of females in each group was high, and was 81.8% in group A (cases 9/11), 90.9% in group B (cases 10/11), and 63.6% in group C (cases 7/11). The subjects who received the investigational agent until the end of the primary evaluation period were 10/11 cases (90.9%) in group A, 10/11 cases (90.9%) in group B, and 9/11 cases (81.8%) in group C; and the subjects that can be observed during the full duration (the primary evaluation period and the extension period) were 10/11 cases (90.9%) in group A, 7/11 cases (63.6%) in group B, and 7/11 cases (63.6%) in group C. (1) Pharmacokinetics
[0132] Evaluation method: Observation and testing were carried out according to Tables 2 and 3. Where it is not particularly specified, the evaluations were carried out before the administration of the investigative agent. Even if the defined primary evaluation period did not reach completion, when the evaluation was carried out on the day of the initial administration or after the extension period, subsequent observation and testing for the primary evaluation period was determined to be unnecessary. The test periods were defined as below.
[0133] Primary evaluation period: In principle, the observation and test period starting from the first day of administration of the investigative agent until weeks 32, 28, and 24 for groups A, B, and C, respectively, this time in that serious concentrations of SA237 were expected to be eliminated. However, in the case when the serum SA237 concentration was confirmed as undetectable level and administration in the extension period started before the end of the above period, the primary evaluation period would be adjusted to the period until observation and testing before the first administration in the extension period.
[0134] Extension period: Starting from the initial administration in the extension period following the completion of the primary evaluation period, and until observation and testing in week 24 of the extension period.
[0135] Post-observation period: Starting from the completion of observation and testing in week 24 of the extension period and up to week 32. [Table 2] OBSERVATION AND TEST SCHEDULE (PRIMARY EVALUATION PERIOD)

[Table 3] OBSERVATION AND TEST SCHEDULE (EXTENSION PERIOD AND MONITORING PERIOD)


[0136] Results: Graphs indicating pharmacokinetics in this study are shown in Fig. 1. The minimum levels of serum SA237 concentration were approximately constant from week 4 and onwards both in the primary assessment period for group A and in the extension period. On the other hand, serum SA237 concentrations in groups B and C during the primary evaluation period decreased from week 8 and onwards. Since the primary evaluation period and the extension period did not show significant differences in the concentration of serum SA237 and AUC0-2W until week 8, the pharmacokinetics did not change when the administration of SA237 was stopped and then resumed. (2) Pharmacodynamic assessments
[0137] Results: Graphs of pharmacodynamic assessments in this study are shown in Figs. 2 and 3. From week 8 to week 20 in group A during the primary evaluation period, and from week 8 to week 24 during the extension period, where the serum SA237 concentration was maintained at a constant level, and the concentration of serum sIL-6R was also maintained at an approximately constant level. On the other hand, from week 8 onwards in groups B and C during the primary evaluation period, the serum concentration of sIL-6R, which is a PD marker for inhibition of IL-6, decreased along with the reduction in concentration of SA237.
[0138] During the primary evaluation period, CRP, which is a PD marker for IL-6 inhibition, was lower than the lower limit of quantification (0.005 mg / dL) from week 4 to week 20 by approximately half of subjects in group A, and the average also remained low around 0.01 mg / dL. The value increased to 0.1 mg / dL or higher from week 16 and onwards in group B and from week 8 and onward in group C. The percentage of normalization of CRP (0.3 mg / dL or less) also showed a similar trend to the change in the average. The percentages at week 4 for each group were 81.8% to 90.9%; and subsequently, when the percentages at week 20 were compared to those at week 8, group A showed no change of 100%, group B showed a change of 81.8% to 80.0% and was about the same, and the group C showed a decrease of 90.9% to 33.3%. In most subjects and time points, CRP was considered to be decreased from the reference level, as long as the serum SA237 concentration is quantifiable (0.2 μg / mL). (3) Effectiveness
[0139] Assessment method: DAS28 (Modified disease activity record based on 28 joint records) is an indicator for assessing rheumatoid arthritis activity, which is calculated from the following equation using painful joint count (TJC ) and inflamed joint count (SJC) in the 28 joints, ESR, and the "global patient assessment". The change in DAS28 from the start of administration to the final day of observation was examined. Summary statistics (mean, standard deviation, median, minimum value, and maximum value) were calculated for each group and each period. In addition, the clinical remission rate was calculated. TWENTY-EIGHT JOINTS EXAMINED AS TO DAS28


[0140] ACR improvement criteria of 20%, 50%, and 70% (ACR20, ACR50, and ACR70) were assessed as below. ACR IMPROVEMENT CRITERIA

[0141] Results: The DAS28 record time course in the primary evaluation period, which indicates the effectiveness of this exam, is shown below in Table 4. [Table 4]

[0142] DAS28 showed improvement at week 8. After the start of administration of different doses (at week 8) in the primary evaluation period, group A showed even more improvement at DAS28, group B did not show a significant change, and the group C showed a tendency to return to the reference value record.
[0143] The frequency of 20% improvement as per ACR criteria was 70.0% to 81.8% in each of the groups at week 8, the frequency of 50% improvement was 40.0% to 50.0 %, and the frequency of 70% improvement was 18.2% to 30.0%. At week 20 compared to week 8, the frequency of improvement of 20% was maintained in groups A and B, but decreased in group C. The frequencies of improvement of 50% and 70% at week 20 in group A increased to 72.7 % (cases 8/11) and 54.5% (cases 6/11), respectively, compared to values in week 8; however, no significant changes were observed in groups B and C. (4) Evaluation, efficacy and safety of immunogenicity and pharmacokinetics, pharmacodynamics in antibody positive cases
[0144] Anti-SA237 antibodies were detected in a single case for each of groups B and C, that is, 2/33 cases in total. In these two cases, the serum SA237 concentration during the extension period after anti-SA237 antibodies were detected was lower than the lower limit of quantification, and from the time the antibodies were detected and onwards, the increase in the concentration of soluble IL-6 receptor (sIL-6R) and the decrease in CRP concentration due to the administration of SA237 were not observed, and DAS28, CDAI, and SDAI were increased. An adverse event, which was mild diabetes, was seen in one of these two cases after antibodies were detected. This adverse event was not an allergic reaction, but it was an exacerbation of complications. A safety issue has not been observed in repeatedly administering SA237 to both subjects after antibodies have been detected. (5) Conclusion
[0145] When 120 mg of SA237 was administered to RA patients three times at two week intervals, followed by three 120 mg administrations at 4 week intervals from week 8 onwards, a stable serum drug concentration was maintained from week 4 to four weeks after final administration. This resulted in a high concentration of serum sIL-6R and low CRP, and a stable improvement of all items for evaluation of efficacy including DAS28. The incidence of an anti-SA237 antibody for the entire clinical study was 6.1% (cases 2/33), and in cases where an anti-SA237 antibody was detected, the serum SA237 concentration was found to decrease after antibody detection anti-SA237, but safety problems were not observed and immunogenicity was considered acceptable. Consequently, there was no concern with security in this administration regime. Industrial Applicability
[0146] The pharmaceutical compositions or regimen of the present invention can solve the immunogenic problem of generating anti-drug antibody, decrease side effects, and provide a pharmaceutical composition that presents higher therapeutic effects with less burden to the patient since it does not exposes the patient to high doses.

权利要求:
Claims (3)
[0001]
1. Use of an IL-6 receptor antibody comprising a heavy chain having the sequence of SEQ ID NO: 3 and a light chain having the sequence of SEQ ID NO: 4, characterized in that it is for the preparation of a drug for the treatment or prevention of an IL-6 related disease, where the drug is a formulation for subcutaneous administration and is administered three times in the same dose as the routine dose at two-week intervals from the initial administration in the dosing period short interval, and then routinely administered at four week intervals from the final administration in the short interval dosing period, and the routine dose is 120 mg per administration.
[0002]
2. Use according to claim 1, characterized by the fact that the IL-6 receptor antibody is SA237.
[0003]
3. Use according to claim 1 or 2, characterized by the fact that the IL-6 related disease is rheumatoid arthritis, juvenile idiopathic arthritis, systemic onset juvenile idiopathic arthritis, Castleman's disease, systemic lupus erythematosus (SLE) , lupus nephritis, Crohn's disease, lymphoma, ulcerative colitis, anemia, vasculitis, Kawasaki's disease, Still's disease, amyloidosis, multiple sclerosis, transplantation, age-related macular degeneration, ankylosing spondylitis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), IgA nephropathy, osteoarthritis, asthma, diabetic nephropathy, GVHD, endometriosis, hepatitis (NASH), myocardial infarction, arteriosclerosis, sepsis, osteoporosis, diabetes, multiple myeloma, prostate cancer, kidney cancer, non-Hodgkin's lymphoma cells, pancreatic cancer, lung cancer, esophageal cancer, colon cancer, cancer-associated cachexia, cancer nerve invasion, myocardial infarction, choroidal neovascularization associated with myopia, idiopathic choroidal neovascularization, uveitis, chronic thyroiditis, delayed hypersensitivity, contact dermatitis, atopic dermatitis, mesothelioma, polymyositis, dermatomyositis, panuveitis, anterior uveitis, intermediate uveitis, scleritis, keratitis, orbital inflammation, neuritis proliferative vitreoretinopathy, dry eye syndrome, postoperative inflammation, neuromyelitis optica, myasthenia gravis, or pulmonary hypertension.

类似技术:

---

公开号 | 公开日 | 专利标题

---

BR112017014067B1|2021-01-12|uses of an il-6 receptor antibody to treat il-6-related diseases

---

JP6952454B2|2021-10-20|Antitumor T cell response enhancer

---

US10744201B2|2020-08-18|Method for treating rheumatoid arthritis with a human IL-6 receptor antibody and methotrexate

---

CA2626688C|2017-10-03|Agents for treating cardiopathy

---

US20160022812A1|2016-01-28|Therapeutic agents for pancreatic cancer

---

AU2007208678A1|2007-08-02|Therapeutic agents for diseases involving choroidal neovascularization

---

JP2010095445A|2010-04-30|Therapeutic agent for inflammatory myopathy containing il-6 antagonist as active ingredient

---

TW201940194A|2019-10-16|Therapeutic agent for asthma containing il-6 inhibitor

同族专利:

---

公开号 | 公开日

---

CA2972393A1|2016-09-01|

---

RU2730590C2|2020-08-24|

---

RU2017133485A3|2019-09-26|

---

JP6130983B2|2017-05-17|

---

JPWO2016136933A1|2017-04-27|

---

KR101892883B1|2018-10-05|

---

RU2017133485A|2019-03-27|

---

AU2016224409A1|2017-07-20|

---

AU2016224409B2|2021-01-28|

---

KR20180095740A|2018-08-27|

---

JP2017160226A|2017-09-14|

---

AU2021202594A1|2021-05-27|

---

JP6775463B2|2020-10-28|

---

EP3263132A4|2018-08-01|

---

US20180148509A1|2018-05-31|

---

MX2017010858A|2017-12-11|

---

US20210017286A1|2021-01-21|

---

EP3263132A1|2018-01-03|

---

US10774148B2|2020-09-15|

---

KR20170095802A|2017-08-23|

---

WO2016136933A1|2016-09-01|

---

SG11201705093UA|2017-07-28|

---

CN107249637A|2017-10-13|

---

TW201642902A|2016-12-16|

---

BR112017014067A2|2018-01-16|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

JPS5144499B1|1970-08-29|1976-11-29|

---

JPS5334319B2|1971-12-28|1978-09-20|

---

JPS5717624B2|1974-04-17|1982-04-12|

---

US4769320A|1982-07-27|1988-09-06|New England Medical Center Hospitals, Inc.|Immunoassay means and methods useful in human native prothrombin and human abnormal prothorombin determinations|

---

US4689299A|1982-09-30|1987-08-25|University Of Rochester|Human monoclonal antibodies against bacterial toxins|

---

JPH06104071B2|1986-08-24|1994-12-21|財団法人化学及血清療法研究所|Factor IX Monoclonal antibody specific for conformation|

---

US4801687A|1986-10-27|1989-01-31|Bioprobe International, Inc.|Monoclonal antibody purification process using protein A|

---

US5004697A|1987-08-17|1991-04-02|Univ. Of Ca|Cationized antibodies for delivery through the blood-brain barrier|

---

US5670373A|1988-01-22|1997-09-23|Kishimoto; Tadamitsu|Antibody to human interleukin-6 receptor|

---

US5322678A|1988-02-17|1994-06-21|Neorx Corporation|Alteration of pharmacokinetics of proteins by charge modification|

---

US5126250A|1988-09-28|1992-06-30|Eli Lilly And Company|Method for the reduction of heterogeneity of monoclonal antibodies|

---

NZ230786A|1988-09-28|1991-11-26|Lilly Co Eli|A method of reducing the heterogeneity of secreted monoclonal antibodies|

---

US5530101A|1988-12-28|1996-06-25|Protein Design Labs, Inc.|Humanized immunoglobulins|

---

US5202253A|1988-12-30|1993-04-13|Oklahoma Medical Research Foundation|Monoclonal antibody specific for protein C and antibody purification method|

---

JPH0636741B2|1989-11-08|1994-05-18|帝人株式会社|Method for separating human protein C|

---

EP0515571B1|1990-02-16|1998-12-02|Boston Biomedical Research Institute|Hybrid reagents capable of selectively releasing molecules into cells|

---

RU2139351C1|1991-04-25|1999-10-10|Чугаи Сейяку Кабусики Кайся|H- and l-chains of monoclonal antibody pm-1 to human il-6r receptor and their v-region, modified monat, its h- and l-chains and their v-regions, cdr-sequence, dna-sequence|

---

US6136310A|1991-07-25|2000-10-24|Idec Pharmaceuticals Corporation|Recombinant anti-CD4 antibodies for human therapy|

---

US5639641A|1992-09-09|1997-06-17|Immunogen Inc.|Resurfacing of rodent antibodies|

---

JPH08511423A|1993-06-10|1996-12-03|ジェネティックセラピー，インコーポレイテッド|Adenovirus vector for treatment of hemophilia|

---

US8017121B2|1994-06-30|2011-09-13|Chugai Seiyaku Kabushika Kaisha|Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component|

---

IL107742D0|1993-11-24|1994-02-27|Yeda Res & Dev|Chemically-modified binding proteins|

---

US5945311A|1994-06-03|1999-08-31|GSF--Forschungszentrumfur Umweltund Gesundheit|Method for producing heterologous bi-specific antibodies|

---

DE4419399C1|1994-06-03|1995-03-09|Gsf Forschungszentrum Umwelt|Process for the preparation of heterologous bispecific antibodies|

---

US6309636B1|1995-09-14|2001-10-30|Cancer Research Institute Of Contra Costa|Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides|

---

PT783893E|1994-10-07|2012-05-24|Chugai Pharmaceutical Co Ltd|Inhibition of abnormal growth of synovial cells using il-6 antagonist as active ingredient|

---

RU2147442C1|1994-10-21|2000-04-20|Кисимото Тадамицу|Pharmaceutical composition for prophylaxis or treatment of diseases caused by il-6 formation|

---

US6485943B2|1995-01-17|2002-11-26|The University Of Chicago|Method for altering antibody light chain interactions|

---

US5731168A|1995-03-01|1998-03-24|Genentech, Inc.|Method for making heteromultimeric polypeptides|

---

US5830478A|1995-06-07|1998-11-03|Boston Biomedical Research Institute|Method for delivering functional domains of diphtheria toxin to a cellular target|

---

US5783186A|1995-12-05|1998-07-21|Amgen Inc.|Antibody-induced apoptosis|

---

TWI240627B|1996-04-26|2005-10-01|Chugai Pharmaceutical Co Ltd|Erythropoietin solution preparation|

---

CZ399A3|1996-07-19|1999-06-16|Amgen Inc.|Polypeptide analogs of cation-active polypeptides|

---

US5990286A|1996-12-18|1999-11-23|Techniclone, Inc.|Antibodies with reduced net positive charge|

---

US6277375B1|1997-03-03|2001-08-21|Board Of Regents, The University Of Texas System|Immunoglobulin-like domains with increased half-lives|

---

CA2284271C|1997-03-21|2012-05-08|Chugai Seiyaku Kabushiki Kaisha|A preventive or therapeutic agent for sensitized t cell-mediated diseases comprising il-6 antagonist as an active ingredient|

---

US6884879B1|1997-04-07|2005-04-26|Genentech, Inc.|Anti-VEGF antibodies|

---

US20070059302A1|1997-04-07|2007-03-15|Genentech, Inc.|Anti-vegf antibodies|

---

US20020187150A1|1997-08-15|2002-12-12|Chugai Seiyaku Kabushiki Kaisha|Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient|

---

EP1916020A3|1997-08-15|2008-07-02|Chugai Seiyaku Kabushiki Kaisha|Preventives and/or remedies for systemic lupus erythematosus containing anti-IL-6 receptor antibody as the active ingredient|

---

JP3992298B2|1997-10-03|2007-10-17|中外製薬株式会社|Natural humanized antibody|

---

CN1204147C|1998-02-25|2005-06-01|利思进药品公司|Enhancing circulating half-life of antibody-based fusion proteins|

---

CN100374159C|1998-03-17|2008-03-12|中外制药株式会社|Preventives or remedies for inflammatory intestinal diseases contg. as active ingredient IL-6 antagonists|

---

CA2325346A1|1998-04-03|1999-10-14|Chugai Seiyaku Kabushiki Kaisha|Humanized antibody against human tissue factor and process for constructing humanized antibody|

---

GB9809951D0|1998-05-08|1998-07-08|Univ Cambridge Tech|Binding molecules|

---

CA2341029A1|1998-08-17|2000-02-24|Abgenix, Inc.|Generation of modified molecules with increased serum half-lives|

---

US6475718B2|1998-09-08|2002-11-05|Schering Aktiengesellschaft|Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus|

---

CN1214043C|1998-12-01|2005-08-10|蛋白质设计实验室股份有限公司|Humanized antibodies to gamma-interferon|

---

US6737056B1|1999-01-15|2004-05-18|Genentech, Inc.|Polypeptide variants with altered effector function|

---

US6972125B2|1999-02-12|2005-12-06|Genetics Institute, Llc|Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith|

---

SK782002A3|1999-07-21|2003-08-05|Lexigen Pharm Corp|FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens|

---

SE9903895D0|1999-10-28|1999-10-28|Active Biotech Ab|Novel compounds|

---

EP1278512A2|2000-05-03|2003-01-29|MBT Munich Biotechnology AG|Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites|

---

KR20120053525A|2000-06-16|2012-05-25|캠브리지 안티바디 테크놀로지 리미티드|Antibodies that immunospecifically bind to blys|

---

AU2002210952B2|2000-10-25|2007-01-11|Chugai Seiyaku Kabushiki Kaisha|Preventives or remedies for psoriasis containing as the active ingredient IL-6 antagonist|

---

WO2002036165A1|2000-10-27|2002-05-10|Chugai Seiyaku Kabushiki Kaisha|Blood mmp-3 level-lowering agent containing il-6 antgonist as the active ingredient|

---

ES2727425T3|2000-12-12|2019-10-16|Medimmune Llc|Molecules with prolonged half-lives, compositions and uses thereof|

---

HU0303428A2|2001-03-07|2004-01-28|Merck Patent Gmbh.|Expression technology for proteins containing a hybrid isotype antibody moiety|

---

MXPA03008955A|2001-04-02|2004-02-18|Chugai Pharmaceutical Co Ltd|Remedies for infant chronic arthritis-relating diseases.|

---

MY138286A|2001-04-13|2009-05-29|Biogen Idec Inc|Antibodies to vla-1|

---

US7667004B2|2001-04-17|2010-02-23|Abmaxis, Inc.|Humanized antibodies against vascular endothelial growth factor|

---

PT2208784E|2001-06-22|2013-04-03|Chugai Pharmaceutical Co Ltd|Cell proliferation inhibitors containing anti-glypican 3 antibody|

---

US20040161741A1|2001-06-30|2004-08-19|Elazar Rabani|Novel compositions and processes for analyte detection, quantification and amplification|

---

US20030049203A1|2001-08-31|2003-03-13|Elmaleh David R.|Targeted nucleic acid constructs and uses related thereto|

---

US7291721B2|2001-11-14|2007-11-06|Centocor, Inc.|Anti-IL-6 antibodies, compositions, methods and uses|

---

US20030224397A1|2002-02-11|2003-12-04|Genentech, Inc.|Antibody variants with faster antigen association rates|

---

EP1475100B1|2002-02-14|2015-05-06|Chugai Seiyaku Kabushiki Kaisha|Use of acetic acid for suppressing Fe ion induced problems in formulations of anti-HM1.24 or anti-IL6R antibodies|

---

AR038568A1|2002-02-20|2005-01-19|Hoffmann La Roche|ANTI-A BETA ANTIBODIES AND ITS USE|

---

US20050130224A1|2002-05-31|2005-06-16|Celestar Lexico- Sciences, Inc.|Interaction predicting device|

---

EP1512015B1|2002-06-12|2009-03-25|Genencor International, Inc.|Methods for improving a binding characteristic of a molecule|

---

WO2003105757A2|2002-06-12|2003-12-24|Genencor International, Inc.|Methods and compositions for milieu-dependent binding of a targeted agent to a target|

---

JP3856734B2|2002-06-28|2006-12-13|株式会社日立製作所|A method for predicting the effectiveness of interferon-beta drug therapy for multiple sclerosis|

---

AU2003264009A1|2002-08-15|2004-03-03|Epitomics, Inc.|Humanized rabbit antibodies|

---

US7217797B2|2002-10-15|2007-05-15|Pdl Biopharma, Inc.|Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis|

---

JP4685764B2|2003-04-10|2011-05-18|アボットバイオセラピューティクスコーポレイション|Modification of antibody FcRn binding affinity or serum half-life by mutagenesis|

---

CA2502904C|2002-10-15|2013-05-28|Protein Design Labs, Inc.|Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis|

---

US7361740B2|2002-10-15|2008-04-22|Pdl Biopharma, Inc.|Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis|

---

SI2270048T1|2002-12-24|2016-01-29|Rinat Neuroscience Corp.|Anti-NGF antibodies and methods using same|

---

JP2006517109A|2003-02-07|2006-07-20|プロテインデザインラブスインコーポレイテッド|Amphiregulin antibodies and their use to treat cancer and psoriasis|

---

CA2516518A1|2003-02-28|2004-09-10|Lonza Biologics Plc.|Antibody purification by protein a and ion exchange chromatography|

---

GB2401040A|2003-04-28|2004-11-03|Chugai Pharmaceutical Co Ltd|Method for treating interleukin-6 related diseases|

---

NZ543712A|2003-06-05|2008-06-30|Genentech Inc|Combination therapy for B cell disorders|

---

EP1636264A2|2003-06-24|2006-03-22|MERCK PATENT GmbH|Tumour necrosis factor receptor molecules with reduced immunogenicity|

---

CA2531482A1|2003-06-30|2005-01-20|Centocor, Inc.|Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses|

---

JP4223346B2|2003-07-18|2009-02-12|京セラミタ株式会社|Image forming apparatus|

---

US20050152894A1|2003-09-05|2005-07-14|Genentech, Inc.|Antibodies with altered effector functions|

---

JP2005101105A|2003-09-22|2005-04-14|Canon Inc|Positioning device, exposure apparatus, and device manufacturing method|

---

AU2003271174A1|2003-10-10|2005-04-27|Chugai Seiyaku Kabushiki Kaisha|Double specific antibodies substituting for functional protein|

---

WO2005035754A1|2003-10-14|2005-04-21|Chugai Seiyaku Kabushiki Kaisha|Double specific antibodies substituting for functional protein|

---

TWI350175B|2003-10-17|2011-10-11|Chugai Pharmaceutical Co Ltd|Mesothelioma therapeutic agent|

---

AU2004291341B2|2003-11-05|2010-08-05|Ares Trading S.A.|Process for the purification of IL-18 binding protein|

---

WO2005047327A2|2003-11-12|2005-05-26|Biogen Idec Ma Inc.|NEONATAL Fc RECEPTOR -BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO|

---

WO2005056606A2|2003-12-03|2005-06-23|Xencor, Inc|Optimized antibodies that target the epidermal growth factor receptor|

---

NZ547157A|2003-12-10|2009-07-31|Medarex Inc|Interferon Alpha Antibodies and their uses|

---

AR048210A1|2003-12-19|2006-04-12|Chugai Pharmaceutical Co Ltd|A PREVENTIVE AGENT FOR VASCULITIS.|

---

US9328169B2|2004-01-09|2016-05-03|Pfizer Inc.|Human antibodies that bind human MAdCAM|

---

DE602005020743D1|2004-02-11|2010-06-02|Warner Lambert Co|PROCESS FOR TREATING OSTEOARTHRITIS WITH ANTI-IL-6 ANTIBODIES|

---

KR20070035482A|2004-03-24|2007-03-30|추가이 세이야쿠 가부시키가이샤|Therapeutic agent for auris interna disorder containing il-6 antagonist as active ingredient|

---

CA2561264A1|2004-03-24|2005-10-06|Xencor, Inc.|Immunoglobulin variants outside the fc region|

---

EP3736295A1|2004-03-24|2020-11-11|Chugai Seiyaku Kabushiki Kaisha|Subtypes of humanized antibody against interleukin-6 receptor|

---

AR048335A1|2004-03-24|2006-04-19|Chugai Pharmaceutical Co Ltd|THERAPEUTIC AGENTS FOR INTERNAL EAR DISORDERS CONTAINING AN IL-6 ANTAGONIST AS AN ACTIVE INGREDIENT|

---

US20050260711A1|2004-03-30|2005-11-24|Deepshikha Datta|Modulating pH-sensitive binding using non-natural amino acids|

---

WO2005112564A2|2004-04-15|2005-12-01|The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services|Germline and sequence variants of humanized antibodies and methods of making and using them|

---

AR049390A1|2004-06-09|2006-07-26|Wyeth Corp|ANTIBODIES AGAINST HUMAN INTERLEUQUINE-13 AND USES OF THE SAME|

---

BRPI0512235A|2004-06-18|2008-02-19|Ambrx Inc|antigen-binding polypeptides and their uses|

---

EP1773391A4|2004-06-25|2009-01-21|Medimmune Inc|Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis|

---

MX2007000105A|2004-07-06|2007-07-18|Bioren Inc|Look-through mutagenesis for developing altered polypeptides with enhanced properties.|

---

KR100863776B1|2004-07-15|2008-10-16|젠코어 인코포레이티드|OPTIMIZED Fc VARIANTS|

---

WO2006030200A1|2004-09-14|2006-03-23|National Institute For Biological Standards And Control|Vaccine|

---

US7563443B2|2004-09-17|2009-07-21|Domantis Limited|Monovalent anti-CD40L antibody polypeptides and compositions thereof|

---

JO3000B1|2004-10-20|2016-09-05|Genentech Inc|Antibody Formulations.|

---

WO2006047350A2|2004-10-21|2006-05-04|Xencor, Inc.|IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION|

---

KR101370253B1|2004-10-22|2014-03-05|암젠 인크|Methods for refolding of recombinant antibodies|

---

US7462697B2|2004-11-08|2008-12-09|Epitomics, Inc.|Methods for antibody engineering|

---

AU2005335714B2|2004-11-10|2012-07-26|Macrogenics, Inc.|Engineering Fc antibody regions to confer effector function|

---

WO2006067847A1|2004-12-22|2006-06-29|Chugai Seiyaku Kabushiki Kaisha|Method of preparing antibody by use of cell having its fucose transporter function inhibited|

---

AT461211T|2004-12-23|2010-04-15|Novo Nordisk As|LIGANDS WITH ANTIBODY-BINDING AFFINITY|

---

US20090087478A1|2004-12-27|2009-04-02|Progenics Pharmaceuticals , Inc.|Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them|

---

EP2476705B1|2004-12-28|2015-10-07|Innate Pharma|Monoclonal antibodies against NKG2A|

---

US8716451B2|2005-01-12|2014-05-06|Kyowa Hakko Kirin Co., Ltd|Stabilized human IgG2 and IgG3 antibodies|

---

WO2006076594A2|2005-01-12|2006-07-20|Xencor, Inc.|Antibodies and fc fusion proteins with altered immunogenicity|

---

GB0502358D0|2005-02-04|2005-03-16|Novartis Ag|Organic compounds|

---

WO2006106905A1|2005-03-31|2006-10-12|Chugai Seiyaku Kabushiki Kaisha|Process for production of polypeptide by regulation of assembly|

---

PT1876236E|2005-04-08|2014-10-22|Chugai Pharmaceutical Co Ltd|Antibody substituting for function of blood coagulation factor viii|

---

JO3058B1|2005-04-29|2017-03-15|Applied Molecular Evolution Inc|Anti-IL-6 Antibodies,Compositions,Methods and uses|

---

EP2221316A1|2005-05-05|2010-08-25|Duke University|Anti-CD19 antibody therapy for autoimmune disease|

---

WO2007021841A2|2005-08-10|2007-02-22|Macrogenics, Inc.|Identification and engineering of antibodies with variant fc regions and methods of using same|

---

CA2619491C|2005-08-19|2016-05-10|Wyeth|Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders|

---

EP1928916A2|2005-09-29|2008-06-11|Viral Logic Systems Technology Corp.|Immunomodulatory compositions and uses therefor|

---

BRPI0617378B1|2005-10-14|2021-08-10|Fukuoka University|USE OF AN IL-6 INHIBITOR TO PRODUCE A PHARMACEUTICAL COMPOSITION TO SUPPRESS DAMAGE TO A TRANSPLANTED ISLET AFTER ISLET TRANSPLANTATION; AND IMPROVING THE VIABILITY OF AN ISLET IN AN ISLET TRANSPLANTATION|

---

CN101330930B|2005-10-21|2011-11-23|中外制药株式会社|Therapeutic agent for heart disease|

---

ES2577292T3|2005-11-07|2016-07-14|Genentech, Inc.|Binding polypeptides with diversified VH / VL hypervariable sequences and consensus|

---

AR057582A1|2005-11-15|2007-12-05|Nat Hospital Organization|AGENTS TO DELETE INDUCTION OF CYTOTOXIC T LYMPHOCYTES|

---

WO2007060411A1|2005-11-24|2007-05-31|Ucb Pharma S.A.|Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r|

---

AR057941A1|2005-11-25|2007-12-26|Univ Keio|THERAPEUTIC AGENTS FOR PROSTATE CANCER|

---

EP1977763A4|2005-12-28|2010-06-02|Chugai Pharmaceutical Co Ltd|Antibody-containing stabilizing preparation|

---

DK2548577T3|2005-12-29|2017-03-13|Janssen Biotech Inc|HUMAN ANTI-IL-23 ANTIBODIES, COMPOSITIONS, PROCEDURES AND APPLICATIONS|

---

AR059213A1|2006-01-27|2008-03-19|Univ Keio|THERAPEUTIC AGENTS FOR DISEASES INVOLVING COROIDAL NEOVASCULARIZATION|

---

EP1988922A4|2006-02-03|2010-06-02|Medimmune Llc|Protein formulations|

---

EP2006380A4|2006-03-23|2010-08-11|Kyowa Hakko Kirin Co Ltd|Agonistic antibody directed against human thrombopoietin receptor|

---

ES2654040T3|2006-03-31|2018-02-12|Chugai Seiyaku Kabushiki Kaisha|Antibody modification method for the purification of bispecific antibodies|

---

US11046784B2|2006-03-31|2021-06-29|Chugai Seiyaku Kabushiki Kaisha|Methods for controlling blood pharmacokinetics of antibodies|

---

CA2647029A1|2006-04-05|2007-10-18|Abbott Biotechnology Ltd.|Antibody purification|

---

WO2007116962A1|2006-04-07|2007-10-18|Osaka University|Muscle regeneration promoter|

---

TWI422387B|2006-05-25|2014-01-11|Glaxo Group Ltd|Immunoglobulins|

---

MY147468A|2006-06-02|2012-12-14|Regeneron Pharma|High affinity antibodies to human il-6 receptor|

---

US8080248B2|2006-06-02|2011-12-20|Regeneron Pharmaceuticals, Inc.|Method of treating rheumatoid arthritis with an IL-6R antibody|

---

ES2544888T3|2006-06-08|2015-09-04|Chugai Seiyaku Kabushiki Kaisha|Prevention or remedy for inflammatory diseases|

---

JP2010500876A|2006-08-18|2010-01-14|アブリンクスエン．ヴェー．|Amino acid sequence directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6 mediated signaling|

---

US20100034194A1|2006-10-11|2010-02-11|Siemens Communications Inc.|Eliminating unreachable subscribers in voice-over-ip networks|

---

EP3424950A1|2006-10-06|2019-01-09|The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services|Prevention of tissue ischemia, related methods and compositions|

---

CN101646459B|2007-01-23|2014-02-12|国立大学法人信州大学|Chronic rejection inhibitor|

---

WO2008092117A2|2007-01-25|2008-07-31|Xencor, Inc.|Immunoglobulins with modifications in the fcr binding region|

---

EP2361095B1|2008-11-25|2017-12-20|AlderBio Holdings LLC|Antagonists of il-6 to raise albumin and/or lower crp|

---

US20100291023A1|2007-05-31|2010-11-18|Genmab A/S|Method for extending the half-life of exogenous or endogenous soluble molecules|

---

CN101796408B|2007-06-29|2014-05-07|奎斯特诊断投资公司|Analysis of amino acids in body fluid by liquid chromatography-mass spectrometry|

---

WO2009010539A2|2007-07-19|2009-01-22|Ablynx. N.V.|Receptor for interleukin-6 from macaca fascicularis|

---

JP5424330B2|2007-07-26|2014-02-26|国立大学法人大阪大学|A therapeutic agent for ocular inflammatory diseases comprising an interleukin 6 receptor inhibitor as an active ingredient|

---

EP2031064A1|2007-08-29|2009-03-04|Boehringer Ingelheim Pharma GmbH & Co. KG|Method for increasing protein titres|

---

AU2008298904B2|2007-09-14|2014-10-16|Amgen Inc.|Homogeneous antibody populations|

---

PL2202245T3|2007-09-26|2017-02-28|Chugai Seiyaku Kabushiki Kaisha|Method of modifying isoelectric point of antibody via amino acid substitution in cdr|

---

WO2009041734A1|2007-09-26|2009-04-02|Kyowa Hakko Kirin Co., Ltd.|Agonistic antibody against human thrombopoietin receptor|

---

CN101939425B|2007-09-26|2014-05-14|中外制药株式会社|Anti-IL-6 receptor antibody|

---

SG193868A1|2007-09-26|2013-10-30|Chugai Pharmaceutical Co Ltd|Modified antibody constant region|

---

AU2008305851B2|2007-09-28|2014-12-18|Chugai Seiyaku Kabushiki Kaisha|Anti-glypican-3 antibody having improved kinetics in plasma|

---

JP5264752B2|2007-10-02|2013-08-14|中外製薬株式会社|Graft-versus-host disease therapeutic agent comprising an interleukin 6 receptor inhibitor as an active ingredient|

---

JO3076B1|2007-10-17|2017-03-15|Janssen Alzheimer Immunotherap|Immunotherapy regimes dependent on apoe status|

---

EP2236604B1|2007-12-05|2016-07-06|Chugai Seiyaku Kabushiki Kaisha|Anti-nr10 antibody and use thereof|

---

WO2009085200A2|2007-12-21|2009-07-09|Amgen Inc.|Anti-amyloid antibodies and uses thereof|

---

KR101666229B1|2008-02-08|2016-10-14|메디뮨 엘엘씨|Anti-ifnar1 antibodies with reduced fc ligand affinity|

---

NZ717429A|2008-04-11|2018-07-27|Chugai Pharmaceutical Co Ltd|Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly|

---

MX2010011717A|2008-05-01|2010-11-30|Amgen Inc|Anti-hepcidin antibodies and methods of use.|

---

TWI528973B|2008-06-05|2016-04-11|Chugai Pharmaceutical Co Ltd|Nerve infiltration inhibitor|

---

TWI440469B|2008-09-26|2014-06-11|Chugai Pharmaceutical Co Ltd|Improved antibody molecules|

---

WO2010098863A1|2009-02-26|2010-09-02|Lpath, Inc.|Humanized platelet activating factor antibody design using anti-lipid antibody templates|

---

US20120071634A1|2009-03-19|2012-03-22|Chugai Seiyaku Kabushiki Kaisha|Antibody Constant Region Variant|

---

WO2010106812A1|2009-03-19|2010-09-23|Chugai Seiyaku Kabushiki Kaisha|Pharmaceutical formulation containing improved antibody molecules|

---

WO2010107110A1|2009-03-19|2010-09-23|中外製薬株式会社|Antibody constant region variant|

---

TWI457134B|2009-03-19|2014-10-21|Chugai Pharmaceutical Co Ltd|Rheumatoid arthritis treatment|

---

SG178190A1|2009-07-31|2012-03-29|Shin Maeda|Cancer metastasis inhibitor|

---

WO2011037158A1|2009-09-24|2011-03-31|中外製薬株式会社|Modified antibody constant regions|

---

JP6101489B2|2010-01-28|2017-03-22|アブ バイオサイエンシズ インコーポレイテッド|Antibody with reduced affinity and method for producing the same|

---

JP5889181B2|2010-03-04|2016-03-22|中外製薬株式会社|Antibody constant region variants|

---

EP2545079A2|2010-03-11|2013-01-16|Rinat Neuroscience Corporation|ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING|

---

TWI667257B|2010-03-30|2019-08-01|中外製藥股份有限公司|Antibodies with modified affinity to fcrn that promote antigen clearance|

---

JP6051049B2|2010-05-28|2016-12-21|中外製薬株式会社|Anti-tumor T cell response enhancer|

---

EP2578233B1|2010-05-28|2017-04-26|National Cancer Center|Therapeutic agent for pancreatic cancer|

---

CN104998254A|2010-11-08|2015-10-28|基因技术公司|Subcutaneously administered anti-IL-6 receptor antibody|

---

EP2639305A4|2010-11-11|2014-04-23|Sysmex Corp|Markers for detecting human follicular helper t cells and method for detecting human follicular helper t cells|

---

US20140234340A1|2010-11-30|2014-08-21|Chugai Seiyaku Kabushiki Kaisha|Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly|

---

CN113416256A|2011-11-30|2021-09-21|中外制药株式会社|Drug comprising transporter that enters into cell to form immune complex|

---

SG10201805584YA|2012-02-24|2018-08-30|Chugai Pharmaceutical Co Ltd|ANTIGEN-BINDING MOLECULE FOR PROMOTING DISAPPEARANCE OF ANTIGEN VIA FcγRIIB|

---

CA2827923C|2011-02-25|2021-11-23|Chugai Seiyaku Kabushiki Kaisha|Fc.gamma.riib-specific fc antibody|

---

BR112013021725A2|2011-02-28|2016-11-01|Genentech Inc|biological markers and methods for predicting response to b-cell antagonists|

---

TW201817745A|2011-09-30|2018-05-16|日商中外製藥股份有限公司|Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance|

---

US20150050269A1|2011-09-30|2015-02-19|Chugai Seiyaku Kabushiki Kaisha|Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities|

---

US20150299313A1|2011-10-05|2015-10-22|Chugai Seiyaku Kabushiki Kaisha|Antigen-binding molecule for promoting clearance from plasma of antigen comprising suger chain receptor-binding domain|

---

US20150353630A1|2012-05-30|2015-12-10|Chugai Seiyaku Kabushiki Kaisha|Antigen-binding molecule for eliminating aggregated antigens|

---

JP6309521B2|2012-08-13|2018-04-11|リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ．|Anti-PCSK9 antibody with pH-dependent binding properties|

---

EP2968985A2|2013-03-15|2016-01-20|Amgen, Inc.|Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9|

---

US9321686B2|2013-03-15|2016-04-26|Forta Corporation|Reinforcement fiber coating compositions, methods of making and treating, and uses for improved adhesion to asphalt and portland cement concrete|

---

WO2014163101A1|2013-04-02|2014-10-09|中外製薬株式会社|Fc region variant|

---

EP3009518B1|2013-06-11|2020-08-12|National Center of Neurology and Psychiatry|Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis patient, and method for determining applicability of novel therapy|

---

NZ711451A|2014-03-07|2016-05-27|Alexion Pharma Inc|Anti-c5 antibodies having improved pharmacokinetics|

---

SG11201705093UA|2015-02-27|2017-07-28|Chugai Pharmaceutical Co Ltd|Composition for treating il-6-related diseases|

---

US10697883B2|2015-05-19|2020-06-30|National Center Of Neurology And Psychiatry|Method for determining application of therapy to multiple sclerosis patient|

---

US10943336B2|2016-08-04|2021-03-09|Intel Corporation|Tone-mapping high dynamic range images|GB2401040A|2003-04-28|2004-11-03|Chugai Pharmaceutical Co Ltd|Method for treating interleukin-6 related diseases|

---

US11046784B2|2006-03-31|2021-06-29|Chugai Seiyaku Kabushiki Kaisha|Methods for controlling blood pharmacokinetics of antibodies|

---

PL2202245T3|2007-09-26|2017-02-28|Chugai Seiyaku Kabushiki Kaisha|Method of modifying isoelectric point of antibody via amino acid substitution in cdr|

---

NZ717429A|2008-04-11|2018-07-27|Chugai Pharmaceutical Co Ltd|Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly|

---

TWI440469B|2008-09-26|2014-06-11|Chugai Pharmaceutical Co Ltd|Improved antibody molecules|

---

WO2010107110A1|2009-03-19|2010-09-23|中外製薬株式会社|Antibody constant region variant|

---

US20120071634A1|2009-03-19|2012-03-22|Chugai Seiyaku Kabushiki Kaisha|Antibody Constant Region Variant|

---

KR102223417B1|2009-10-26|2021-03-05|에프. 호프만-라 로슈 아게|Method for the production of a glycosylated immunoglobulin|

---

CN104998254A|2010-11-08|2015-10-28|基因技术公司|Subcutaneously administered anti-IL-6 receptor antibody|

---

EP3009518B1|2013-06-11|2020-08-12|National Center of Neurology and Psychiatry|Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosispatient, and method for determining applicability of novel therapy|

---

SG11201705093UA|2015-02-27|2017-07-28|Chugai Pharmaceutical Co Ltd|Composition for treating il-6-related diseases|

---

US10697883B2|2015-05-19|2020-06-30|National Center Of Neurology And Psychiatry|Method for determining application of therapy to multiple sclerosispatient|

---

JP2021504482A|2017-11-30|2021-02-15|バイオ−テラ ソリュ−ションズ，エルティーディー．|Liquid formulation of humanized antibody for the treatment of IL-6 related diseases|

---

CN108567981A|2018-07-17|2018-09-25|漯河医学高等专科学校|Application of the antagonist of interleukin-6 in preparing inhibition Notch-1 protein expressions, treating the drug of cancer of pancreas|

---

WO2020027279A1|2018-08-01|2020-02-06|Chugai Seiyaku Kabushiki Kaisha|A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease|

---

KR102167640B1|2018-08-16|2020-10-19|한국전력기술 주식회사|A method for simulating the flow of a reactor coolant in reactor core and a core simplification model for applying to the model|

---

WO2021241720A1|2020-05-29|2021-12-02|中外製薬株式会社|Antibody-containing formulation|

法律状态:
2019-10-01| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |

---

2020-06-09| B07E| Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|

---

2020-07-21| B07A| Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]|

---

2020-11-03| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|

---

2021-01-12| B16A| Patent or certificate of addition of invention granted|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/02/2016, OBSERVADAS AS CONDICOES LEGAIS. |

优先权:

---

申请号 | 申请日 | 专利标题

---

JP2015-037933|2015-02-27|

---

JP2015037933|2015-02-27|

---

PCT/JP2016/055768|WO2016136933A1|2015-02-27|2016-02-26|Composition for treating il-6-related diseases|

---